page 1 drug consumption in current year (period 201801...

Drug consumption in current year (Period 201801 - 201812)

WholesaleATC code Subgroup or chemical substance DDD/1000 inhab./day Hospital % Change % price/1000 € Hospital % Change %

A ALIMENTARY TRACT AND METABOLISM 292,86 4 -11 298 491 7 -16A01 STOMATOLOGICAL PREPARATIONS 2,80 7 -53 1 910 7 -21A01A STOMATOLOGICAL PREPARATIONS 2,80 7 -53 1 910 7 -21A01AA Caries prophylactic agents 0,45 10 -89 619 12 -54A01AA01 sodium fluoride 0,45 10 -89 498 15 -54A01AA03 olaflur - - - 50 1 4A01AA51 sodium fluoride, combinations - - - 71 1 -65A01AB Antiinfectives for local oral treatment 2,31 7 15 1 052 6 12A01AB03 chlorhexidine 2,09 7 17 825 7 17A01AB11 various 0,22 0 -5 227 0 -5A01AB22 doxycycline - - - 0 100 -A01AC Corticosteroids for local oral treatment - - - 135 1 -6A01AC01 triamcinolone - - - 135 1 -6A01AD Other agents for local oral treatment 0,04 0 - 104 0 -A01AD02 benzydamine 0,04 0 - 104 0 -A02 DRUGS FOR ACID RELATED DISORDERS 69,32 3 -7 35 102 5 -17A02A ANTACIDS 2,20 1 -4 3 357 1 -1A02AA Magnesium compounds 0,08 22 -23 172 22 11A02AA04 magnesium hydroxide 0,08 22 -23 172 22 11A02AD Combinations and complexes of aluminium, 2,12 0 -3 3 185 0 -1

calcium and magnesium compoundsA02AD01 ordinary salt combinations 2,12 0 -3 3 185 0 -1A02B DRUGS FOR PEPTIC ULCER AND 67,12 3 -7 31 746 5 -18

GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD)

A02BA H2-receptor antagonists 1,10 4 0 1 008 7 -4A02BA02 ranitidine 0,99 3 0 621 3 -2A02BA03 famotidine 0,11 10 -6 387 14 -5A02BB Prostaglandins 0,03 71 22 64 71 22A02BB01 misoprostol 0,03 71 22 64 71 22A02BC Proton pump inhibitors 64,75 3 -8 28 167 5 -20A02BC01 omeprazole 9,29 2 -6 2 701 3 -15A02BC02 pantoprazole 33,31 5 4 11 337 8 -16



A02BC03 lansoprazole 5,82 0 -10 2 655 0 -16A02BC04 rabeprazole 1,37 0 8 760 0 11A02BC05 esomeprazole 14,96 2 -26 10 714 3 -27A02BD Combinations for eradication of Helicobacter pylori 0,03 0 -4 309 0 -4A02BD03 lansoprazole, metronidazole and amoxicillin 0,01 0 -3 72 0 -3A02BD07 lansoprazole, amoxicillin and clarithromycin 0,02 0 -4 238 0 -4A02BX Other drugs for peptic ulcer and 1,20 8 1 2 197 7 6

gastro-oesophageal reflux disease (GORD)A02BX02 sucralfate 0,26 21 6 411 21 6A02BX13 alginic acid 0,94 4 -1 1 786 4 6A03 DRUGS FOR FUNCTIONAL 2,65 10 4 5 490 44 -5

GASTROINTESTINAL DISORDERSA03A DRUGS FOR FUNCTIONAL 1,02 7 10 1 772 18 -2

GASTROINTESTINAL DISORDERSA03AB Synthetic anticholinergics, quaternary ammonium 0,04 90 2 307 90 2

compoundsA03AB02 glycopyrronium bromide 0,04 90 2 307 90 2A03AX Other drugs for functional gastrointestinal disorders 0,98 4 11 1 464 3 -3A03AX13 silicones 0,98 4 11 1 464 3 -3A03B BELLADONNA AND DERIVATIVES, PLAIN 0,06 92 -22 546 92 -3A03BA Belladonna alkaloids, tertiary amines 0,05 91 -10 456 92 7A03BA01 atropine 0,05 91 -10 456 92 7A03BB Belladonna alkaloids semisynthetic, quaternary 0,00 95 -73 90 95 -35

ammonium compoundsA03BB01 butylscopolamine 0,00 95 -73 90 95 -35A03C ANTISPASMODICS IN COMBINATION WITH 0,20 1 -16 194 1 -16

PSYCHOLEPTICSA03CA Synthetic anticholinergic agents in combination 0,20 1 -16 194 1 -16

with psycholepticsA03CA02 clidinium and psycholeptics 0,20 1 -16 194 1 -16A03D ANTISPASMODICS IN COMBINATION WITH 0,38 8 20 2 577 57 -4

ANALGESICSA03DA Synthetic anticholinergic agents in combination 0,38 8 20 2 577 57 -4

with analgesics



A03DA02 pitofenone and analgesics 0,38 8 20 2 577 57 -4A03F PROPULSIVES 0,99 11 -1 401 33 -13A03FA Propulsives 0,99 11 -1 401 33 -13A03FA01 metoclopramide 0,99 11 -1 401 33 -13A04 ANTIEMETICS AND ANTINAUSEANTS 0,25 48 -9 3 729 46 -32A04A ANTIEMETICS AND ANTINAUSEANTS 0,25 48 -9 3 729 46 -32A04AA Serotonin (5HT3) antagonists 0,18 56 1 2 783 46 -10A04AA01 ondansetron 0,15 51 3 1 048 44 -10A04AA02 granisetron 0,03 68 -12 487 67 -45A04AA05 palonosetron 0,01 97 15 317 99 -40A04AA55 palonosetron, combinations - - - 930 20 84A04AD Other antiemetics 0,07 29 -28 947 44 -61A04AD01 scopolamine 0,06 27 7 299 27 7A04AD12 aprepitant 0,01 40 -71 633 52 -70A04AD14 rolapitant 0,00 52 - 14 66 291A05 BILE AND LIVER THERAPY 0,83 2 6 2 101 3 -2A05A BILE THERAPY 0,83 2 6 2 101 3 -2A05AA Bile acids and derivatives 0,83 2 6 2 101 3 -2A05AA02 ursodeoxycholic acid 0,83 2 6 2 101 3 -2A06 DRUGS FOR CONSTIPATION 45,41 10 1 25 596 13 0A06A DRUGS FOR CONSTIPATION 45,41 10 1 25 596 13 0A06AB Contact laxatives 6,29 7 -5 3 788 9 -3A06AB02 bisacodyl 0,97 5 -10 385 6 -10A06AB06 senna glycosides 0,29 0 -7 119 0 -7A06AB08 sodium picosulfate 5,02 8 -4 2 653 7 -3A06AB56 senna glycosides, combinations - - - 183 0 -9A06AB58 sodium picosulfate, combinations 0,00 29 5 448 29 5A06AC Bulk-forming laxatives 9,96 0 1 4 883 2 2A06AC01 ispaghula (psylla seeds) 9,34 0 2 4 640 2 3A06AC51 ispaghula, combinations 0,62 2 -6 244 2 -6A06AD Osmotically acting laxatives 27,62 14 3 13 670 15 -1A06AD11 lactulose 14,19 11 -5 2 867 11 -5A06AD15 macrogol 13,43 16 13 8 940 15 7A06AD17 sodium phosphate - - - 51 17 -31



A06AD65 macrogol, combinations - - - 1 813 21 -24A06AG Enemas 1,43 18 -1 2 636 23 -2A06AG02 bisacodyl 0,28 41 -7 466 40 -7A06AG10 docusate sodium, incl. combinations 0,06 54 -9 614 51 -7A06AG11 laurilsulfate, incl. combinations 1,09 10 1 1 557 7 1A06AH Peripheral opioid receptor antagonists 0,07 38 58 443 51 25A06AH01 methylnaltrexone bromide 0,00 93 -18 119 93 -18A06AH03 naloxegol 0,07 35 67 324 36 55A06AX Other drugs for constipation 0,04 12 14 175 14 11A06AX04 linaclotide 0,02 2 2 77 2 -8A06AX05 prucalopride 0,02 24 31 98 23 31A07 ANTIDIARRHEALS, INTESTINAL 13,43 2 -1 28 852 5 -1

ANTIINFLAMMATORY/ANTIINFECTIVE AGENTSA07A INTESTINAL ANTIINFECTIVES 0,08 28 17 1 738 44 -2A07AA Antibiotics 0,08 28 17 1 738 44 -2A07AA02 nystatin 0,03 26 2 189 292 27 1 287A07AA09 vancomycin 0,01 56 0 670 56 0A07AA11 rifaximin 0,05 25 -23 545 25 -23A07AA12 fidaxomicin 0,00 77 -39 231 77 -39A07B INTESTINAL ADSORBENTS 0,14 48 -7 691 48 -5A07BA Charcoal preparations 0,14 48 -7 691 48 -5A07BA01 medicinal charcoal 0,14 48 -7 691 48 -5A07C ELECTROLYTES WITH CARBOHYDRATES 0,01 6 -7 269 6 -1A07CA Oral rehydration salt formulations 0,01 6 -7 269 6 -1A07D ANTIPROPULSIVES 1,31 2 -1 4 284 1 2A07DA Antipropulsives 1,31 2 -1 4 284 1 2A07DA03 loperamide 1,31 2 -1 3 215 1 -1A07DA06 eluxadoline 0,00 0 - 19 1 51A07DA53 loperamide, combinations - - - 1 050 0 12A07E INTESTINAL ANTIINFLAMMATORY AGENTS 10,40 1 2 17 076 1 3A07EA Corticosteroids acting locally 0,30 3 -5 1 671 3 5A07EA02 hydrocortisone 0,00 0 -100 0 0 -100A07EA06 budesonide 0,30 3 9 1 671 3 12A07EB Antiallergic agents, excl.corticosteroids 0,00 17 -107 -1 17 -107



A07EB01 cromoglicic acid 0,00 17 -107 -1 17 -107A07EC Aminosalicylic acid and similar agents 10,11 1 2 15 405 1 3A07EC01 sulfasalazine 3,24 1 -1 2 904 1 -1A07EC02 mesalazine 6,85 1 4 12 478 1 4A07EC03 olsalazine 0,01 1 -19 23 1 -19A07F ANTIDIARRHEAL MICROORGANISMS 1,48 6 -17 4 373 6 -17A07FA Antidiarrheal microorganisms 1,48 6 -17 4 373 6 -17A07FA01 lactic acid producing organisms 0,05 1 -28 72 1 -27A07FA02 saccharomyces boulardii 1,43 6 -16 4 301 6 -17A07X OTHER ANTIDIARRHEALS - - - 422 4 124A07XA Other antidiarrheals - - - 422 4 124A07XA04 racecadotril - - - 422 4 124A08 ANTIOBESITY PREPARATIONS, EXCL. DIET 0,09 1 -14 558 0 59

PRODUCTSA08A ANTIOBESITY PREPARATIONS, EXCL. DIET 0,09 1 -14 558 0 59

PRODUCTSA08AA Centrally acting antiobesity products - - - 266 0 3 450A08AA62 bupropion and naltrexone - - - 266 0 3 450A08AB Peripherally acting antiobesity products 0,09 1 -14 292 1 -15A08AB01 orlistat 0,09 1 -14 292 1 -15A09 DIGESTIVES, INCL. ENZYMES 0,92 4 -3 2 613 4 7A09A DIGESTIVES, INCL. ENZYMES 0,92 4 -3 2 613 4 7A09AA Enzyme preparations 0,92 4 -3 2 613 4 7A09AA02 multienzymes (lipase, protease etc.) 0,92 4 -3 2 613 4 7A10 DRUGS USED IN DIABETES 95,76 2 -21 154 780 2 -24A10A INSULINS AND ANALOGUES 32,14 3 -26 63 808 3 -27A10AB Insulins and analogues for injection, fast-acting 10,29 3 -16 16 240 3 -17A10AB01 insulin (human) 0,09 37 -16 108 37 -16A10AB04 insulin lispro 1,87 2 -38 2 896 2 -39A10AB05 insulin aspart 7,82 3 -9 12 413 3 -9A10AB06 insulin glulisine 0,51 2 -15 823 2 -15A10AC Insulins and analogues, intermediate-acting 0,72 10 -11 1 018 10 -10A10AC01 insulin (human) 0,72 10 -11 1 018 10 -10A10AD Insulins and analogues, intermediate-acting 0,43 5 -20 743 5 -20

combined with fast-acting



A10AD01 insulin (human) - - -100 0 - -100A10AD04 insulin lispro 0,03 4 -58 49 4 -58A10AD05 insulin aspart 0,41 5 -14 694 5 -14A10AE Insulins and analogues, long-acting 20,68 2 -31 45 807 2 -31A10AE04 insulin glargine 13,69 2 -40 28 682 2 -41A10AE05 insulin detemir 6,60 2 -3 15 962 2 -4A10AE06 insulin degludec 0,40 2 195 1 162 2 91A10AE54 insulin glargine and lixisenatide - - - 0 0 -A10B BLOOD GLUCOSE LOWERING DRUGS, EXCL. 63,63 1 -18 90 972 1 -21

INSULINSA10BA Biguanides 32,16 1 -10 11 241 1 -8A10BA02 metformin 32,16 1 -10 11 241 1 -8A10BB Sulfonylureas 1,41 1 -20 138 1 -20A10BB07 glipizide - - -100 0 - -100A10BB12 glimepiride 1,41 1 -20 138 1 -19A10BD Combinations of oral blood glucose lowering drugs 5,87 0 -41 13 744 0 -40A10BD05 metformin and pioglitazone 0,01 0 -94 17 0 -94A10BD07 metformin and sitagliptin 4,36 1 -50 9 669 1 -50A10BD08 metformin and vildagliptin 0,63 0 -5 1 477 0 -6A10BD09 pioglitazone and alogliptin 0,01 0 -1 22 0 -2A10BD10 metformin and saxagliptin 0,02 0 -7 45 0 -7A10BD11 metformin and linagliptin 0,20 0 8 463 0 7A10BD13 metformin and alogliptin 0,01 0 0 31 0 -1A10BD15 metformin and dapagliflozin 0,33 0 47 776 0 46A10BD19 linagliptin and empagliflozin - - - 141 0 -A10BD20 metformin and empagliflozin 0,29 0 - 1 083 0 99A10BD21 saxagliptin and dapagliflozin - - - 20 0 1 488A10BD24 sitagliptin and ertugliflozin - - - 0 0 -A10BG Thiazolidinediones 0,56 1 -6 811 1 -3A10BG03 pioglitazone 0,56 1 -6 811 1 -3A10BH Dipeptidyl peptidase 4 (DPP-4) inhibitors 13,47 2 -39 30 050 2 -40A10BH01 sitagliptin 8,21 2 -52 18 649 2 -53A10BH02 vildagliptin 1,08 2 -11 2 317 2 -12A10BH03 saxagliptin 0,06 1 -15 144 1 -14



A10BH04 alogliptin 0,04 1 -9 85 1 -9A10BH05 linagliptin 4,08 3 13 8 855 4 13A10BJ Glucagon-like peptide-1 (GLP-1) analogues 3,31 1 10 18 060 1 7A10BJ01 exenatide 0,54 1 -12 3 030 1 -13A10BJ02 liraglutide 2,39 1 17 13 128 1 13A10BJ03 lixisenatide 0,00 1 33 27 1 29A10BJ05 dulaglutide 0,37 1 9 1 876 1 8A10BK Sodium-glucose co-transporter 2 (SGLT2) 6,67 1 39 16 879 1 36

inhibitorsA10BK01 dapagliflozin 2,67 1 21 6 267 1 21A10BK03 empagliflozin 4,00 1 54 10 609 1 46A10BK04 ertugliflozin 0,00 2 - 2 2 -A10BX Other blood glucose lowering drugs, excl. insulins 0,18 1 -2 50 2 -47A10BX01 guar gum - - - 4 1 -94A10BX02 repaglinide 0,18 1 -2 46 2 40A11 VITAMINS 21,00 4 -9 9 322 13 -4A11C VITAMIN A AND D, INCL. COMBINATIONS OF 0,48 5 9 934 4 7

THE TWOA11CC Vitamin D and analogues 0,48 5 9 934 4 7A11CC01 ergocalciferol (vitamin D2) - - - 11 2 -17A11CC02 dihydrotachysterol 0,06 3 11 78 3 11A11CC03 alfacalcidol 0,42 5 9 409 8 10A11CC05 colecalciferol (vitamin D3) - - - 436 1 3A11D VITAMIN B1, PLAIN AND IN COMBINATION 5,25 12 -8 2 262 49 -3

WITH VITAMIN B6 AND B12A11DA Vitamin B1, plain 0,49 99 1 1 073 99 4A11DA01 thiamine (vit B1) 0,49 99 1 1 073 99 4A11DB Vitamin B1 in comb. with vitamin B6 and/or 4,75 3 -9 1 189 4 -9

vitamin B12A11E VITAMIN B-COMPLEX, INCL. COMBINATIONS 12,81 1 -5 5 744 1 -5A11EA Vitamin B-complex 2,74 4 -1 1 033 4 -1A11EX Vitamin B-complex, other combinations 10,07 0 -7 4 711 0 -6A11G ASCORBIC ACID (VITAMIN C), INCL. 2,19 1 -28 146 1 -28

COMBINATIONS



A11GA Ascorbic acid (vit C), plain 2,19 1 -28 146 1 -28A11GA01 ascorbic acid (vit C) 2,19 1 -28 146 1 -28A11H OTHER PLAIN VITAMIN PREPARATIONS 0,27 7 -18 236 3 -8A11HA Other plain vitamin preparations 0,27 7 -18 236 3 -8A11HA02 pyridoxine (vit B6) 0,15 13 -9 48 13 -9A11HA03 tocopherol (vit E) 0,12 1 -27 27 1 -27A11HA30 dexpanthenol - - - 161 1 -4A12 MINERAL SUPPLEMENTS 40,35 3 4 15 792 5 5A12A CALCIUM 34,55 3 3 10 806 2 3A12AA Calcium 1,10 2 9 815 2 6A12AA02 calcium glubionate - - -100 0 - -100A12AA04 calcium carbonate 1,10 2 10 809 2 9A12AA06 calcium lactate gluconate 0,00 9 -74 6 9 -73A12AX Calcium, combinations with vitamin D and/or other 33,45 3 3 9 991 2 3

drugsA12B POTASSIUM 5,70 8 5 4 909 9 8A12BA Potassium 5,70 8 5 4 909 9 8A12BA01 potassium chloride 5,65 8 5 4 780 9 8A12BA51 potassium chloride, combinations 0,05 3 4 130 3 12A12C OTHER MINERAL SUPPLEMENTS 0,10 47 39 77 47 39A12CA Sodium 0,10 47 39 77 47 39A12CA01 sodium chloride 0,10 47 39 77 47 39A14 ANABOLIC AGENTS FOR SYSTEMIC USE 0,02 25 -18 18 25 -18A14A ANABOLIC STEROIDS 0,02 25 -18 18 25 -18A14AB Estren derivatives 0,02 25 -18 18 25 -18A14AB01 nandrolone 0,02 25 -18 18 25 -18A16 OTHER ALIMENTARY TRACT AND 0,02 44 -3 12 627 42 2

METABOLISM PRODUCTSA16A OTHER ALIMENTARY TRACT AND 0,02 44 -3 12 627 42 2

METABOLISM PRODUCTSA16AB Enzymes 0,01 58 6 11 108 47 7A16AB03 agalsidase alfa 0,00 60 2 1 837 60 1A16AB04 agalsidase beta 0,01 43 7 8 008 42 6A16AB05 laronidase 0,00 100 21 311 100 21



A16AB07 alglucosidase alfa 0,00 100 4 356 100 4A16AB09 idursulfase - - - 3 100 -96A16AB10 velaglucerase alfa 0,00 6 63 592 6 62A16AX Various alimentary tract and metabolism products 0,01 6 -21 1 519 8 -27A16AX03 sodium phenylbutyrate 0,00 4 -26 272 4 -26A16AX04 nitisinone 0,00 0 13 529 0 0A16AX06 miglustat 0,00 6 -73 304 6 -74A16AX08 teduglutide 0,00 100 100 38 100 100A16AX09 glycerol phenylbutyrate - - - 28 26 -A16AX10 eliglustat 0,00 0 - 208 0 -A16AX14 migalastat 0,00 0 - 100 0 -A16AX15 telotristat 0,00 100 - 40 100 -B BLOOD AND BLOOD FORMING ORGANS 135,64 4 -5 238 033 29 -2B01 ANTITHROMBOTIC AGENTS 115,10 4 -4 116 488 17 16B01A ANTITHROMBOTIC AGENTS 115,10 4 -4 116 488 17 16B01AA Vitamin K antagonists 12,64 2 -14 2 896 2 -15B01AA03 warfarin 12,64 2 -14 2 896 2 -15B01AB Heparin group 6,86 36 -4 25 144 40 -1B01AB01 heparin 0,08 94 -1 810 94 -8B01AB02 antithrombin 0,00 100 50 451 100 50B01AB04 dalteparin 0,55 3 -26 1 387 3 -28B01AB05 enoxaparin 5,29 40 -7 16 307 41 -7B01AB09 danaparoid 0,00 74 -25 200 74 -25B01AB10 tinzaparin 0,94 26 45 5 989 33 36B01AC Platelet aggregation inhibitors excl. heparin 81,55 2 -8 20 059 7 -6B01AC04 clopidogrel 8,38 3 3 1 372 22 -9B01AC06 acetylsalicylic acid 67,14 1 -10 7 731 1 -12B01AC07 dipyridamole 0,45 2 -16 391 2 -15B01AC11 iloprost 0,00 67 -12 304 41 -15B01AC13 abciximab 0,00 100 -51 69 100 -50B01AC16 eptifibatide 0,00 100 -48 89 100 -48B01AC17 tirofiban 0,00 100 -23 51 100 -23B01AC21 treprostinil 0,00 6 21 2 015 7 21B01AC22 prasugrel 0,02 24 -48 82 24 -48



B01AC24 ticagrelor 0,80 4 7 3 301 4 7B01AC25 cangrelor 0,00 100 18 137 100 18B01AC27 selexipag 0,00 6 -5 543 12 -23B01AC30 combinations 4,75 2 -5 3 975 2 -5B01AD Enzymes 0,00 100 -35 4 967 100 -32B01AD02 alteplase 0,00 100 -39 4 046 100 -34B01AD07 reteplase 0,00 100 -50 252 100 -50B01AD11 tenecteplase 0,00 99 -3 669 99 -3B01AE Direct thrombin inhibitors 2,46 2 19 11 284 5 11B01AE03 argatroban 0,00 100 -32 52 100 -32B01AE06 bivalirudin 0,00 100 -26 211 100 -46B01AE07 dabigatran etexilate 2,46 2 19 11 021 2 14B01AF Direct factor Xa inhibitors 11,56 3 66 51 214 3 59B01AF01 rivaroxaban 5,99 2 42 25 299 3 34B01AF02 apixaban 5,25 3 98 24 362 4 90B01AF03 edoxaban 0,33 2 252 1 554 3 239B01AX Other antithrombotic agents 0,02 13 3 923 83 -1B01AX01 defibrotide 0,00 99 -1 750 99 -1B01AX05 fondaparinux 0,02 13 3 174 14 0B02 ANTIHEMORRHAGICS 0,32 23 -16 58 389 28 -24B02A ANTIFIBRINOLYTICS 0,25 20 10 1 789 73 9B02AA Amino acids 0,24 20 10 1 680 71 6B02AA02 tranexamic acid 0,24 20 10 1 680 71 6B02AB Proteinase inhibitors 0,00 100 195 109 100 99B02AB01 aprotinin 0,00 100 1 567 40 100 1 926B02AB02 alfa1 antitrypsin 0,00 100 30 69 100 30B02B VITAMIN K AND OTHER HEMOSTATICS 0,08 35 -51 56 600 26 -25B02BA Vitamin K 0,02 87 -48 156 87 -48B02BA01 phytomenadione 0,02 87 -48 156 87 -48B02BB Fibrinogen 0,00 100 -22 1 484 100 -22B02BB01 fibrinogen, human 0,00 100 -22 1 484 100 -22B02BC Local hemostatics - - - 3 391 99 -2B02BC30 combinations - - - 3 391 99 -2B02BD Blood coagulation factors 0,03 19 -73 47 523 20 -29



B02BD01 coagulation factor IX, II, VII and X in combination 0,00 100 -62 5 738 100 -13B02BD02 coagulation factor VIII 0,02 4 -72 25 506 4 -25B02BD03 factor VIII inhibitor bypassing activity 0,00 30 -78 1 307 22 -44B02BD04 coagulation factor IX 0,01 8 -78 6 533 6 -53B02BD06 von Willebrand factor and coagulation factor VIII in - - - 6 467 18 1

combinationB02BD07 coagulation factor XIII 0,00 33 -79 739 33 -49B02BD08 coagulation factor VIIa - - - 464 84 -39B02BD10 von Willebrand factor 0,00 20 -51 769 43 -19B02BX Other systemic hemostatics 0,03 8 34 4 046 8 34B02BX04 romiplostim 0,01 9 29 1 331 9 28B02BX05 eltrombopag 0,02 8 37 2 700 8 36B02BX06 emicizumab 0,00 0 - 16 0 -B03 ANTIANEMIC PREPARATIONS 20,22 6 -13 26 176 26 1B03A IRON PREPARATIONS 5,76 4 12 9 268 52 28B03AA Iron bivalent, oral preparations 4,21 4 4 3 054 3 10B03AA01 ferrous glycine sulphate 3,09 4 3 2 454 3 11B03AA07 ferrous sulphate 1,12 3 6 600 3 6B03AB Iron trivalent, oral preparations 1,50 2 42 1 231 3 31B03AB05 ferric oxide polymaltose complexes 1,50 2 42 1 229 3 31B03AB10 ferric maltol - - - 2 6 3 353B03AC Iron, parenteral preparations 0,05 100 55 4 919 95 42B03AD Iron in combination with folic acid - - - 64 2 2B03AD01 ferrous amino acid complex - - - 64 2 2B03B VITAMIN B12 AND FOLIC ACID 13,40 6 -21 1 951 6 -38B03BA Vitamin B12 (cyanocobalamin and derivatives) 6,15 7 -37 1 160 6 -51B03BA01 cyanocobalamin 1,10 4 -76 364 4 -77B03BA03 hydroxocobalamin 5,05 7 -2 796 7 -2B03BB Folic acid, combinations 7,26 6 1 791 6 2B03BB01 folic acid 7,26 6 1 791 6 2B03X OTHER ANTIANEMIC PREPARATIONS 1,06 13 -2 14 957 13 -4B03XA Other antianemic preparations 1,06 13 -2 14 957 13 -4B03XA01 erythropoietin 0,17 18 -35 2 014 18 -38B03XA02 darbepoetin alfa 0,72 12 10 10 397 12 7



B03XA03 methoxy polyethylene glycolepoetin beta 0,17 10 5 2 546 10 0B05 BLOOD SUBSTITUTES AND PERFUSION - - - 31 955 77 -1

SOLUTIONSB05A BLOOD AND RELATED PRODUCTS - - - 3 638 100 8B05AA Blood substitutes and plasma protein fractions - - - 3 638 100 8B05AA01 albumin - - - 3 606 100 8B05AA05 dextran - - - 1 100 -88B05AA06 gelatin agents - - - 15 98 -35B05AA07 hydroxyethylstarch - - - 15 96 -23B05B I.V. SOLUTIONS - - - 19 209 99 -5B05BA Solutions for parenteral nutrition - - - 5 213 100 3B05BA01 amino acids - - - 110 100 -12B05BA02 fat emulsions - - - 47 97 -6B05BA03 carbohydrates - - - 460 99 0B05BA10 combinations - - - 4 595 100 4B05BB Solutions affecting the electrolyte balance - - - 13 968 99 -8B05BB01 electrolytes - - - 12 886 99 -8B05BB02 electrolytes with carbohydrates - - - 1 082 100 -6B05BC Solutions producing osmotic diuresis - - - 28 99 3B05BC01 mannitol - - - 28 99 3B05D PERITONEAL DIALYTICS - - - 7 664 7 4B05DA Isotonic solutions - - - 3 934 5 -4B05DB Hypertonic solutions - - - 3 730 8 15B05X I.V. SOLUTION ADDITIVES - - - 1 277 98 6B05XA Electrolyte solutions - - - 842 98 7B05XA01 potassium chloride - - - 295 100 -3B05XA03 sodium chloride - - - 181 94 -3B05XA05 magnesium sulphate - - - 74 100 665B05XA06 potassium phosphate, incl. comb. with other - - - 34 98 -12

potassium saltsB05XA14 sodium glycerophosphate - - - 68 97 16B05XA31 electrolytes in combination with other drugs - - - 190 98 0B05XB Amino acids - - - 41 100 0B05XB02 alanyl glutamine - - - 41 100 0



B05XC Vitamins - - - 394 99 5B05Z HEMODIALYTICS AND HEMOFILTRATES - - - 167 100 58B05ZB Hemofiltrates - - - 167 100 58B06 OTHER HEMATOLOGICAL AGENTS 0,00 21 -12 5 025 19 -16B06A OTHER HEMATOLOGICAL AGENTS 0,00 21 -12 5 025 19 -16B06AC Drugs used in hereditary angioedema 0,00 21 -12 5 025 19 -16B06AC01 c1-inhibitor, plasma derived 0,00 17 1 2 745 17 1B06AC02 icatibant 0,00 13 -35 1 977 13 -35B06AC04 conestat alfa 0,00 75 148 303 75 24C CARDIOVASCULAR SYSTEM 591,51 2 -4 171 984 10 -24C01 CARDIAC THERAPY 14,80 9 -9 23 072 57 -2C01A CARDIAC GLYCOSIDES 2,26 4 -9 1 128 12 -6C01AA Digitalis glycosides 2,26 4 -9 1 128 12 -6C01AA05 digoxin 2,26 4 -9 1 128 12 -6C01B ANTIARRHYTHMICS, CLASS I AND III 2,06 4 -33 4 094 34 -36C01BB Antiarrhythmics, class IB 0,00 97 -42 181 97 -42C01BB01 lidocaine 0,00 97 -42 181 97 -42C01BC Antiarrhythmics, class IC 1,43 1 -42 1 942 1 -43C01BC04 flecainide 1,43 1 -42 1 942 1 -43C01BD Antiarrhythmics, class III 0,63 12 4 1 209 34 6C01BD01 amiodarone 0,49 15 6 516 60 29C01BD05 ibutilide 0,00 99 -18 87 99 -19C01BD07 dronedarone 0,14 1 -4 607 1 -4C01BG Other antiarrhythmics, class I and III 0,00 100 -49 762 100 -49C01BG11 vernakalant 0,00 100 -49 762 100 -49C01C CARDIAC STIMULANTS EXCL. CARDIAC 0,93 86 54 12 247 84 20

GLYCOSIDESC01CA Adrenergic and dopaminergic agents 0,92 86 54 7 369 73 25C01CA01 etilefrine 0,06 25 7 392 75 13C01CA03 norepinephrine 0,06 99 3 1 504 99 19C01CA04 dopamine 0,00 85 -3 37 86 -7C01CA06 phenylephrine 0,01 99 195 512 100 16C01CA07 dobutamine 0,00 99 9 82 99 9C01CA24 epinephrine 0,79 89 65 4 525 59 33



C01CA26 ephedrine - - - 318 99 1C01CE Phosphodiesterase inhibitors 0,00 100 - 417 100 -C01CE02 milrinone 0,00 100 - 417 100 -C01CX Other cardiac stimulants 0,00 100 3 4 461 100 3C01CX08 levosimendan 0,00 100 3 4 461 100 3C01D VASODILATORS USED IN CARDIAC DISEASES 9,52 4 -5 4 779 12 -5C01DA Organic nitrates 9,52 4 -5 4 779 12 -5C01DA02 glyceryl trinitrate 0,65 10 -10 1 045 33 -6C01DA08 isosorbide dinitrate 1,63 6 -6 1 082 13 -4C01DA14 isosorbide mononitrate 7,23 3 -4 2 652 3 -5C01E OTHER CARDIAC PREPARATIONS 0,03 61 5 824 94 8C01EA Prostaglandins 0,00 98 2 276 98 2C01EA01 alprostadil 0,00 98 2 276 98 2C01EB Other cardiac preparations 0,03 61 5 548 92 11C01EB10 adenosine 0,02 100 -2 363 98 10C01EB17 ivabradine 0,01 4 14 38 4 13C01EB21 regadenoson 0,00 100 13 146 100 15C02 ANTIHYPERTENSIVES 3,00 3 0 6 979 8 -27C02A ANTIADRENERGIC AGENTS, CENTRALLY 2,52 3 -1 1 247 30 0

ACTINGC02AC Imidazoline receptor agonists 2,52 3 -1 1 247 30 0C02AC01 clonidine 0,06 36 5 373 87 18C02AC02 guanfacine 0,03 18 -6 236 18 -12C02AC05 moxonidine 2,43 2 -1 638 2 -3C02C ANTIADRENERGIC AGENTS, PERIPHERALLY 0,43 4 8 342 4 9

ACTINGC02CA Alpha-adrenoceptor blocking agents 0,43 4 8 342 4 9C02CA01 prazosin 0,43 4 8 342 4 9C02K OTHER ANTIHYPERTENSIVES 0,05 2 -18 5 391 3 -33C02KX Antihypertensives for pulmonary arterial 0,05 2 -18 5 391 3 -33

hypertensionC02KX01 bosentan 0,02 2 -5 1 010 3 -47C02KX02 ambrisentan 0,01 2 -43 816 3 -48C02KX04 macitentan 0,02 3 -33 2 450 3 -35



C02KX05 riociguat 0,01 1 33 1 115 1 37C03 DIURETICS 51,56 6 -11 8 232 18 -6C03A LOW-CEILING DIURETICS, THIAZIDES 6,67 2 2 1 223 2 4C03AA Thiazides, plain 6,67 2 2 1 223 2 4C03AA03 hydrochlorothiazide 6,67 2 2 1 223 2 4C03B LOW-CEILING DIURETICS, EXCL. THIAZIDES 0,48 1 -4 183 1 -6C03BA Sulfonamides, plain 0,48 1 -4 183 1 -6C03BA11 indapamide 0,48 1 -4 183 1 -6C03C HIGH-CEILING DIURETICS 35,11 8 1 4 709 28 6C03CA Sulfonamides, plain 35,11 8 1 4 709 28 6C03CA01 furosemide 35,11 8 1 4 709 28 6C03D POTASSIUM-SPARING AGENTS 2,57 3 -2 1 304 3 0C03DA Aldosterone antagonists 2,57 3 -2 1 304 3 0C03DA01 spironolactone 2,55 3 -2 1 233 3 0C03DA04 eplerenone 0,01 3 3 71 3 4C03E DIURETICS AND POTASSIUM-SPARING 6,75 1 -50 770 2 -48

AGENTS IN COMBINATIONC03EA Low-ceiling diuretics and potassium-sparing 5,89 1 -53 615 1 -53

agentsC03EA01 hydrochlorothiazide and potassium-sparing agents 5,89 1 -53 615 1 -53C03EB High-ceiling diuretics and potassium-sparing 0,85 5 -12 155 5 -12

agentsC03EB01 furosemide and potassium-sparing agents 0,85 5 -12 155 5 -12C03X OTHER DIURETICS 0,00 93 -77 42 93 -77C03XA Vasopressin antagonists 0,00 93 -77 42 93 -77C03XA01 tolvaptan 0,00 93 -77 42 93 -77C04 PERIPHERAL VASODILATORS 0,11 5 -5 79 5 -5C04A PERIPHERAL VASODILATORS 0,11 5 -5 79 5 -5C04AD Purine derivatives 0,11 5 -5 79 5 -5C04AD03 pentoxifylline 0,11 5 -5 79 5 -5C05 VASOPROTECTIVES - - - 4 584 4 -1C05A AGENTS FOR TREATMENT OF - - - 2 898 2 -2

HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE



C05AA Corticosteroids - - - 2 648 2 3C05AA01 hydrocortisone - - - 58 28 -11C05AA04 prednisolone - - - 2 190 1 0C05AA08 fluocortolone - - - 400 2 20C05AE Muscle relaxants - - - 125 4 -48C05AE01 glyceryl trinitrate - - - 125 4 -48C05AX Other agents for treatment of hemorrhoids and - - - 124 0 2

anal fissures for topical useC05AX03 other preparations, combinations - - - 124 0 2C05B ANTIVARICOSE THERAPY - - - 1 686 8 0C05BA Heparins or heparinoids for topical use - - - 1 571 2 -1C05BA01 organo-heparinoid - - - 1 571 2 -1C05BB Sclerosing agents for local injection - - - 115 86 17C05BB02 polidocanol - - - 115 86 17C07 BETA BLOCKING AGENTS 63,55 2 -2 21 350 5 -10C07A BETA BLOCKING AGENTS 58,32 2 0 18 582 5 -9C07AA Beta blocking agents, non-selective 2,44 2 -14 1 083 2 -13C07AA05 propranolol 2,14 2 2 995 2 -3C07AA07 sotalol 0,30 2 -60 88 2 -60C07AB Beta blocking agents, selective 53,59 2 1 16 196 3 -9C07AB02 metoprolol 10,33 2 -9 5 388 5 -14C07AB03 atenolol 2,05 2 -2 408 2 -3C07AB04 acebutolol 0,15 3 -5 80 3 -5C07AB05 betaxolol 0,68 1 -9 247 1 -9C07AB07 bisoprolol 38,69 2 4 9 559 2 -6C07AB09 esmolol 0,00 100 -18 25 100 -9C07AB12 nebivolol 1,69 1 5 489 1 5C07AG Alpha and beta blocking agents 2,28 2 -2 1 303 35 -10C07AG01 labetalol 0,09 8 -5 601 73 4C07AG02 carvedilol 2,20 2 -2 702 2 -19C07B BETA BLOCKING AGENTS AND THIAZIDES 3,72 0 -19 1 322 0 -23C07BB Beta blocking agents, selective, and thiazides 3,72 0 -19 1 322 0 -23C07BB02 metoprolol and thiazides 0,62 0 -54 290 0 -54C07BB07 bisoprolol and thiazides 3,10 0 -5 984 0 -5



C07BB12 nebivolol and thiazides - - - 48 0 7C07F BETA BLOCKING AGENTS, OTHER 1,50 0 -6 1 446 0 -6

COMBINATIONSC07FB Beta blocking agent and calcium channel blockers 1,50 0 -6 1 446 0 -6C07FB02 metoprolol and felodipine 1,50 0 -6 1 446 0 -6C08 CALCIUM CHANNEL BLOCKERS 83,58 1 2 15 798 3 -11C08C SELECTIVE CALCIUM CHANNEL BLOCKERS 82,04 1 3 14 793 3 -11

WITH MAINLY VASCULAR EFFECTSC08CA Dihydropyridine derivatives 82,04 1 3 14 793 3 -11C08CA01 amlodipine 55,05 1 2 4 288 2 -25C08CA02 felodipine 7,46 1 4 3 345 1 -3C08CA03 isradipine 0,22 1 -16 139 1 -26C08CA05 nifedipine 1,69 2 -27 911 3 -19C08CA06 nimodipine 0,01 83 -3 274 95 -26C08CA07 nisoldipine 0,03 3 -67 38 3 -68C08CA10 nilvadipine 0,77 1 -1 463 1 -1C08CA13 lercanidipine 16,82 1 9 5 336 1 2C08D SELECTIVE CALCIUM CHANNEL BLOCKERS 1,54 2 -4 1 004 6 -6

WITH DIRECT CARDIAC EFFECTSC08DA Phenylalkylamine derivatives 0,73 2 0 285 16 -4C08DA01 verapamil 0,73 2 0 285 16 -4C08DB Benzothiazepine derivatives 0,81 2 -8 720 2 -7C08DB01 diltiazem 0,81 2 -8 720 2 -7C09 AGENTS ACTING ON THE 253,77 1 5 46 539 1 -8

RENIN-ANGIOTENSIN SYSTEMC09A ACE INHIBITORS, PLAIN 105,10 2 2 9 248 2 -1C09AA ACE inhibitors, plain 105,10 2 2 9 248 2 -1C09AA02 enalapril 22,96 1 1 2 161 2 -3C09AA03 lisinopril 3,71 1 -2 736 2 -14C09AA04 perindopril 4,60 1 3 1 734 1 -2C09AA05 ramipril 73,73 2 2 4 587 2 2C09AA06 quinapril 0,10 1 -14 30 1 -14C09B ACE-INHIBITORS, COMBINATIONS 11,93 0 -2 4 793 0 -10C09BA ACE-inhibitors and diuretics 10,11 0 -3 3 510 0 -8



C09BA02 enalapril and diuretics 6,71 0 -4 2 085 0 -13C09BA03 lisinopril and diuretics 1,33 0 2 683 0 2C09BA04 perindopril and diuretics 1,01 1 -2 537 0 -2C09BA05 ramipril and diuretics 0,98 0 -4 172 0 -4C09BA06 quinapril and diuretics 0,08 0 -15 33 0 -16C09BA15 zofenopril and diuretics - - - 0 0 -C09BB ACE inhibitors and calcium channel blockers 1,47 0 1 935 0 -22C09BB02 enalapril and lercanidipine 0,35 0 1 124 0 0C09BB04 perindopril and amlodipine 1,12 0 11 811 0 -18C09BB05 ramipril and felodipine - - -100 0 - -100C09BX ACE inhibitors, other combinations 0,35 0 17 348 0 15C09BX01 perindopril, amlodipine and indapamide 0,33 0 11 334 0 12C09BX02 perindopril and bisoprolol 0,02 0 480 14 0 461C09C ANGIOTENSIN II RECEPTOR BLOCKERS 104,30 1 11 15 536 1 -17

(ARBs), PLAINC09CA Angiotensin II receptor blockers (ARBs), plain 104,30 1 11 15 536 1 -17C09CA01 losartan 42,54 1 10 7 612 1 -18C09CA02 eprosartan 0,37 1 -8 321 1 -13C09CA03 valsartan 15,12 1 15 2 249 2 -17C09CA06 candesartan 36,84 1 13 4 095 1 -11C09CA07 telmisartan 8,36 1 5 1 048 2 -22C09CA08 olmesartan medoxomil 1,07 0 6 210 1 -54C09D ANGIOTENSIN II RECEPTOR BLOCKERS 32,44 0 2 16 961 1 -1

(ARBs), COMBINATIONSC09DA Angiotensin II receptor blockers (ARBs) and 28,15 0 2 9 751 0 -10

diureticsC09DA01 losartan and diuretics 12,11 0 4 3 542 0 -7C09DA02 eprosartan and diuretics 0,38 0 -7 347 0 -7C09DA03 valsartan and diuretics 4,76 0 7 1 256 0 -16C09DA06 candesartan and diuretics 6,97 0 1 3 434 0 -3C09DA07 telmisartan and diuretics 3,59 0 -4 1 013 0 -25C09DA08 olmesartan medoxomil and diuretics 0,35 0 -2 159 0 -24C09DB Angiotensin II receptor blockers (ARBs) and 2,59 0 -3 3 295 0 -3

calcium channel blockers



C09DB01 valsartan and amlodipine 2,47 0 -1 3 173 0 -1C09DB02 olmesartan medoxomil and amlodipine 0,12 0 -32 122 0 -41C09DX Angiotensin II receptor blockers (ARBs), other 1,69 1 10 3 915 2 31

combinationsC09DX01 valsartan, amlodipine and hydrochlorothiazide 1,49 0 4 2 181 0 4C09DX04 valsartan and sacubitril 0,20 4 94 1 735 4 94C09X OTHER AGENTS ACTING ON THE - - -100 0 - -100

RENIN-ANGIOTENSIN SYSTEMC09XA Renin-inhibitors - - -100 0 - -100C09XA02 aliskiren - - -100 0 - -100C10 LIPID MODIFYING AGENTS 121,15 1 -19 45 352 1 -49C10A LIPID MODIFYING AGENTS, PLAIN 121,05 1 -19 44 980 1 -49C10AA HMG CoA reductase inhibitors 115,38 1 -18 38 999 1 -43C10AA01 simvastatin 37,15 1 -3 17 095 1 -20C10AA02 lovastatin 0,31 1 -3 240 1 1C10AA03 pravastatin 2,24 2 -1 1 295 2 -1C10AA04 fluvastatin 1,90 1 -14 837 1 -23C10AA05 atorvastatin 49,59 1 -36 11 362 2 -66C10AA07 rosuvastatin 24,20 1 20 8 171 1 -27C10AB Fibrates 0,53 2 -1 447 2 -7C10AB02 bezafibrate 0,06 1 -1 77 1 -2C10AB04 gemfibrozil 0,02 1 -13 20 1 -13C10AB05 fenofibrate 0,44 2 0 350 2 -8C10AC Bile acid sequestrants 0,06 2 -43 173 2 -41C10AC01 colestyramine 0,06 2 -45 159 2 -45C10AC04 colesevelam 0,00 0 313 14 0 313C10AX Other lipid modifying agents 5,08 1 -38 5 360 2 -71C10AX09 ezetimibe 5,06 1 -38 4 874 2 -73C10AX13 evolocumab 0,02 5 112 432 5 68C10AX14 alirocumab 0,00 0 1 071 54 0 715C10B LIPID MODIFYING AGENTS, COMBINATIONS 0,10 0 -60 372 0 -48C10BA HMG CoA reductase inhibitors in combination with 0,10 0 -60 253 1 -60

other lipid modifying agentsC10BA02 simvastatin and ezetimibe 0,10 0 -60 253 1 -60



C10BX HMG CoA reductase inhibitors, other combinations - - - 119 0 55C10BX11 atorvastatin, amlodipine and perindopril - - - 119 0 55D DERMATOLOGICALS 2,85 1 5 41 560 5 2D01 ANTIFUNGALS FOR DERMATOLOGICAL USE 1,55 1 7 5 816 3 4D01A ANTIFUNGALS FOR TOPICAL USE - - - 4 668 4 3D01AA Antibiotics - - - 44 4 6D01AA02 natamycin - - - 44 4 6D01AC Imidazole and triazole derivatives - - - 3 023 5 6D01AC01 clotrimazole - - - 256 1 9D01AC02 miconazole - - - 978 8 14D01AC07 tioconazole - - - 29 2 -57D01AC08 ketoconazole - - - 960 2 3D01AC20 imidazoles/triazoles in combination with - - - 800 7 6

corticosteroidsD01AE Other antifungals for topical use - - - 1 602 1 -3D01AE14 ciclopirox - - - 70 0 -4D01AE15 terbinafine - - - 1 335 2 -4D01AE16 amorolfine - - - 197 0 3D01B ANTIFUNGALS FOR SYSTEMIC USE 1,55 1 7 1 148 1 9D01BA Antifungals for systemic use 1,55 1 7 1 148 1 9D01BA02 terbinafine 1,55 1 7 1 148 1 9D02 EMOLLIENTS AND PROTECTIVES - - - 2 232 1 9D02A EMOLLIENTS AND PROTECTIVES - - - 2 232 1 9D02AE Carbamide products - - - 1 198 1 12D02AE01 carbamide - - - 1 198 1 12D02AX Other emollients and protectives - - - 1 034 0 6D03 PREPARATIONS FOR TREATMENT OF - - - 6 548 3 5

WOUNDS AND ULCERSD03A CICATRIZANTS - - - 6 493 3 5D03AX Other cicatrizants - - - 6 493 3 5D03AX03 dexpanthenol - - - 6 493 3 5D03B ENZYMES - - - 55 68 -14D03BA Proteolytic enzymes - - - 55 68 -14D03BA02 collagenase - - - 55 68 -14



D04 ANTIPRURITICS, INCL. ANTIHISTAMINES, - - - 330 0 74ANESTHETICS, ETC.

D04A ANTIPRURITICS, INCL. ANTIHISTAMINES, - - - 330 0 74ANESTHETICS, ETC.

D04AA Antihistamines for topical use - - - 330 0 74D04AA04 tripelennamine - - - 330 0 74D05 ANTIPSORIATICS 0,15 2 4 2 172 2 -8D05A ANTIPSORIATICS FOR TOPICAL USE - - - 1 777 2 -4D05AX Other antipsoriatics for topical use - - - 1 777 2 -4D05AX02 calcipotriol - - - 38 3 15D05AX03 calcitriol - - - 42 3 -23D05AX52 calcipotriol, combinations - - - 1 696 2 -4D05B ANTIPSORIATICS FOR SYSTEMIC USE 0,15 2 4 395 2 -24D05BB Retinoids for treatment of psoriasis 0,15 2 4 395 2 -24D05BB02 acitretin 0,15 2 4 395 2 -24D06 ANTIBIOTICS AND CHEMOTHERAPEUTICS - - - 5 077 4 -3

FOR DERMATOLOGICAL USED06A ANTIBIOTICS FOR TOPICAL USE - - - 2 255 6 20D06AX Other antibiotics for topical use - - - 2 255 6 20D06AX01 fusidic acid - - - 969 11 16D06AX04 neomycin - - - 1 261 1 24D06AX09 mupirocin - - - 24 15 13D06B CHEMOTHERAPEUTICS FOR TOPICAL USE - - - 2 823 2 -16D06BA Sulfonamides - - - 74 55 -17D06BA01 silver sulfadiazine - - - 74 55 -17D06BB Antivirals - - - 2 246 1 -18D06BB03 aciclovir - - - 1 173 1 -1D06BB04 podophyllotoxin - - - 66 3 -67D06BB06 penciclovir - - - 202 0 -5D06BB10 imiquimod - - - 495 1 16D06BB53 aciclovir, combinations - - - 310 0 -57D06BX Other chemotherapeutics - - - 502 0 -2D06BX01 metronidazole - - - 349 0 2D06BX02 ingenol mebutate - - - 153 1 -10



D07 CORTICOSTEROIDS, DERMATOLOGICAL - - - 11 539 3 2PREPARATIONS

D07A CORTICOSTEROIDS, PLAIN - - - 7 904 3 5D07AA Corticosteroids, weak (group I) - - - 3 529 2 9D07AA02 hydrocortisone - - - 3 529 2 9D07AB Corticosteroids, moderately potent (group II) - - - 1 359 4 5D07AB01 clobetasone - - - 8 1 5D07AB02 hydrocortisone butyrate - - - 714 3 0D07AB08 desonide - - - 637 5 11D07AC Corticosteroids, potent (group III) - - - 2 386 5 0D07AC01 betamethasone - - - 1 439 7 4D07AC03 desoximetasone - - - 70 11 28D07AC13 mometasone - - - 839 2 -9D07AC14 methylprednisolone aceponate - - - 38 0 -11D07AD Corticosteroids, very potent (group IV) - - - 630 4 5D07AD01 clobetasol - - - 630 4 5D07B CORTICOSTEROIDS, COMBINATIONS WITH - - - 1 263 3 -15

ANTISEPTICSD07BA Corticosteroids, weak, combinations with - - - 765 3 7

antisepticsD07BA04 hydrocortisone and antiseptics - - - 765 3 7D07BB Corticosteroids, moderately potent, combinations - - - 307 4 -47

with antisepticsD07BB04 hydrocortisone butyrate and antiseptics - - - 307 4 -47D07BC Corticosteroids, potent, combinations with - - - 190 5 -3

antisepticsD07BC01 betamethasone and antiseptics - - - 190 5 -3D07C CORTICOSTEROIDS, COMBINATIONS WITH - - - 1 570 4 2

ANTIBIOTICSD07CA Corticosteroids, weak, combinations with - - - 921 4 3

antibioticsD07CA01 hydrocortisone and antibiotics - - - 921 4 3D07CC Corticosteroids, potent, combinations with - - - 649 4 0

antibiotics



D07CC01 betamethasone and antibiotics - - - 649 4 0D07X CORTICOSTEROIDS, OTHER COMBINATIONS - - - 802 2 1D07XA Corticosteroids, weak, other combinations - - - 294 0 9D07XA01 hydrocortisone - - - 294 0 9D07XC Corticosteroids, potent, other combinations - - - 508 3 -3D07XC01 betamethasone, combinations - - - 508 3 -3D08 ANTISEPTICS AND DISINFECTANTS - - - 1 059 63 3D08A ANTISEPTICS AND DISINFECTANTS - - - 1 059 63 3D08AC Biguanides and amidines - - - 612 92 7D08AC02 chlorhexidine - - - 229 80 -8D08AC52 chlorhexidine, combinations - - - 382 100 19D08AG Iodine products - - - 448 23 -3D08AG02 povidone-iodine - - - 448 23 -3D09 MEDICATED DRESSINGS - - - 139 24 -19D09A MEDICATED DRESSINGS - - - 139 24 -19D09AA Ointment dressings with antiinfectives - - - 13 33 -7D09AA02 fusidic acid - - - 13 33 -7D09AB Zinc bandages - - - 126 23 -20D09AB01 zinc bandage without supplements - - - 126 23 -20D10 ANTI-ACNE PREPARATIONS 1,07 1 2 3 206 1 3D10A ANTI-ACNE PREPARATIONS FOR TOPICAL - - - 1 806 1 3

USED10AD Retinoids for topical use in acne - - - 483 0 15D10AD01 tretinoin - - - 175 0 34D10AD03 adapalene - - - 179 1 -7D10AD53 adapalene, combinations - - - 130 0 32D10AE Peroxides - - - 474 1 -10D10AE01 benzoyl peroxide - - - 474 1 -10D10AF Antiinfectives for treatment of acne - - - 669 1 5D10AF01 clindamycin - - - 138 2 -32D10AF51 clindamycin, combinations - - - 532 1 22D10AX Other anti-acne preparations for topical use - - - 179 0 2D10AX03 azelaic acid - - - 179 0 2D10B ANTI-ACNE PREPARATIONS FOR SYSTEMIC 1,07 1 2 1 400 1 3

USE



D10BA Retinoids for treatment of acne 1,07 1 2 1 400 1 3D10BA01 isotretinoin 1,07 1 2 1 400 1 3D11 OTHER DERMATOLOGICAL PREPARATIONS 0,08 1 4 3 441 4 2D11A OTHER DERMATOLOGICAL PREPARATIONS 0,08 1 4 3 441 4 2D11AC Medicated shampoos - - - 96 0 2D11AC03 selenium compounds - - - 96 0 2D11AF Wart and anti-corn preparations - - - 0 - -100D11AH Agents for dermatitis, excluding corticosteroids 0,02 3 15 2 037 6 2D11AH01 tacrolimus - - - 1 239 3 -8D11AH02 pimecrolimus - - - 365 1 -1D11AH04 alitretinoin 0,02 1 9 321 1 16D11AH05 dupilumab 0,00 53 - 112 71 -D11AX Other dermatologicals 0,07 0 1 1 308 0 4D11AX01 minoxidil - - - 725 0 8D11AX10 finasteride 0,07 0 1 223 0 1D11AX16 eflornithine - - - 33 0 -20D11AX18 diclofenac - - - 5 5 -7D11AX21 brimonidine - - - 106 0 -11D11AX22 ivermectin - - - 208 0 11D11AX24 deoxycholic acid - - - 8 20 -33G GENITO URINARY SYSTEM AND SEX 136,70 7 -10 110 117 6 -15

HORMONESG01 GYNECOLOGICAL ANTIINFECTIVES AND 0,67 1 -5 2 660 1 -1

ANTISEPTICSG01A ANTIINFECTIVES AND ANTISEPTICS, EXCL. 0,67 1 -5 2 660 1 -1

COMBINATIONS WITH CORTICOSTEROIDSG01AA Antibiotics 0,06 1 -7 395 1 17G01AA10 clindamycin 0,06 1 -7 395 1 17G01AC Quinoline derivatives 0,01 0 149 153 0 149G01AC05 dequalinium 0,01 0 149 153 0 149G01AF Imidazole derivatives 0,59 1 -5 2 112 1 -7G01AF01 metronidazole 0,17 1 -9 855 1 -12G01AF02 clotrimazole 0,28 1 -11 1 063 1 -7G01AF04 miconazole 0,15 2 11 193 2 16



G02 OTHER GYNECOLOGICALS 2,96 10 -51 7 908 34 -47G02A UTEROTONICS 0,00 40 -66 87 99 131G02AB Ergot alkaloids 0,00 27 -72 1 27 -72G02AB01 methylergometrine 0,00 27 -72 1 27 -72G02AD Prostaglandins 0,00 100 164 86 100 153G02AD06 misoprostol 0,00 100 164 86 100 153G02B CONTRACEPTIVES FOR TOPICAL USE 2,93 10 -51 7 396 30 -48G02BA Intrauterine contraceptives - - - 5 540 39 -45G02BA03 plastic IUD with progestogens - - - 5 540 39 -45G02BB Intravaginal contraceptives 2,93 10 -51 1 856 5 -55G02BB01 vaginal ring with progestogen and estrogen 2,93 10 -51 1 856 5 -55G02C OTHER GYNECOLOGICALS 0,03 10 2 425 84 -31G02CB Prolactine inhibitors 0,03 9 4 75 11 4G02CB01 bromocriptine 0,03 9 2 24 9 2G02CB03 cabergoline 0,01 13 3 45 13 3G02CB04 quinagolide 0,00 0 15 6 0 16G02CX Other gynecologicals 0,00 100 -48 350 100 -35G02CX01 atosiban 0,00 100 -48 350 100 -35G03 SEX HORMONES AND MODULATORS OF THE 82,78 10 -14 57 820 5 -12

GENITAL SYSTEMG03A HORMONAL CONTRACEPTIVES FOR 46,09 17 -15 18 928 13 -16

SYSTEMIC USEG03AA Progestogens and estrogens, fixed combinations 28,53 15 -23 11 417 12 -23G03AA07 levonorgestrel and ethinylestradiol 0,59 5 5 160 3 7G03AA09 desogestrel and ethinylestradiol 3,45 9 -3 985 8 -6G03AA10 gestodene and ethinylestradiol 5,37 10 -7 1 432 3 -13G03AA11 norgestimate and ethinylestradiol 0,04 1 -52 13 1 -50G03AA12 drospirenone and ethinylestradiol 14,88 18 -36 6 567 15 -33G03AA13 norelgestromin and ethinylestradiol 0,48 5 -2 289 5 -2G03AA14 nomegestrol and estradiol 3,13 12 1 1 847 12 2G03AA16 dienogest and ethinylestradiol 0,58 45 3 708 125 24 3 436G03AB Progestogens and estrogens, sequential 1,50 6 -6 918 6 -6

preparationsG03AB03 levonorgestrel and ethinylestradiol 0,09 0 -17 40 0 -17



G03AB05 desogestrel and ethinylestradiol 0,01 0 -42 6 0 -42G03AB06 gestodene and ethinylestradiol 0,04 0 -22 20 0 -22G03AB08 dienogest and estradiol 1,36 6 -4 851 6 -4G03AC Progestogens 16,00 21 3 5 495 20 -3G03AC01 norethisterone 0,85 2 7 240 2 5G03AC03 levonorgestrel 0,45 11 10 272 23 6G03AC08 etonogestrel 3,99 48 21 925 49 17G03AC09 desogestrel 10,71 13 -4 4 059 14 -8G03AD Emergency contraceptives 0,05 2 6 1 098 2 7G03AD01 levonorgestrel 0,03 2 1 554 2 -2G03AD02 ulipristal 0,02 1 18 544 1 18G03B ANDROGENS 2,00 0 -4 4 943 0 -5G03BA 3-oxoandrosten (4) derivatives 2,00 0 -4 4 943 0 -5G03BA03 testosterone 2,00 0 -4 4 943 0 -5G03C ESTROGENS 18,96 1 -20 22 320 1 -4G03CA Natural and semisynthetic estrogens, plain 18,25 1 -20 21 998 1 -4G03CA03 estradiol 12,74 0 -25 20 137 1 -5G03CA04 estriol 5,52 1 -5 1 861 1 8G03CX Other estrogens 0,71 0 -5 322 0 -21G03CX01 tibolone 0,71 0 -5 322 0 -21G03D PROGESTOGENS 2,32 1 8 1 473 0 9G03DA Pregnen (4) derivatives 0,43 1 8 533 0 2G03DA02 medroxyprogesterone 0,21 1 14 40 1 14G03DA04 progesterone 0,22 0 2 493 0 1G03DB Pregnadien derivatives 0,47 0 15 428 0 15G03DB01 dydrogesterone 0,38 0 15 206 0 15G03DB08 dienogest 0,09 0 16 222 0 16G03DC Estren derivatives 1,42 1 5 512 1 12G03DC02 norethisterone 1,18 0 5 456 0 12G03DC03 lynestrenol 0,24 2 8 57 2 8G03F PROGESTOGENS AND ESTROGENS IN 9,72 0 -1 4 154 0 0

COMBINATIONG03FA Progestogens and estrogens, combinations 7,60 0 0 3 351 0 0G03FA01 norethisterone and estrogen 2,94 0 1 1 268 0 3



G03FA12 medroxyprogesterone and estrogen 1,23 0 -19 548 0 -19G03FA14 dydrogesterone and estrogen 2,96 0 9 1 188 0 9G03FA17 drospirenone and estrogen 0,47 0 -3 347 0 -3G03FB Progestogens and estrogens, sequential 2,12 0 -2 803 0 1

preparationsG03FB05 norethisterone and estrogen 0,70 0 -2 291 0 4G03FB06 medroxyprogesterone and estrogen 0,15 0 -13 33 0 -13G03FB08 dydrogesterone and estrogen 1,27 0 -1 478 0 -1G03FB09 levonorgestrel and estrogen - - -100 0 - -100G03G GONADOTROPHINS AND OTHER OVULATION 0,22 0 -39 4 401 0 -35

STIMULANTSG03GA Gonadotrophins 0,22 0 -25 4 401 0 -34G03GA01 chorionic gonadotrophin 0,13 0 -16 143 0 -10G03GA02 human menopausal gonadotrophin 0,03 0 -14 1 138 0 -15G03GA04 urofollitropin 0,00 0 603 56 0 603G03GA05 follitropin alfa 0,05 0 -39 1 769 0 -44G03GA06 follitropin beta 0,01 0 -73 216 0 -74G03GA07 lutropin alfa 0,00 8 -61 1 8 -61G03GA08 choriogonadotropin alfa 0,00 0 -34 178 0 -32G03GA09 corifollitropin alfa 0,00 0 -44 290 0 -46G03GA30 combinations - - - 610 0 63G03GB Ovulation stimulants, synthetic - - -100 0 - -100G03GB02 clomifene - - -100 0 - -100G03H ANTIANDROGENS 3,46 3 -7 1 276 1 -8G03HA Antiandrogens, plain preparations 0,05 6 -2 135 7 -5G03HA01 cyproterone 0,05 6 -2 135 7 -5G03HB Antiandrogens and estrogens 3,40 3 -7 1 141 1 -9G03HB01 cyproterone and estrogen 3,40 3 -7 1 141 1 -9G03X OTHER SEX HORMONES AND MODULATORS 0,03 22 -79 325 45 -73

OF THE GENITAL SYSTEMG03XB Progesterone receptor modulators 0,03 22 -79 325 45 -73G03XB01 mifepristone 0,01 98 -45 152 96 -42G03XB02 ulipristal 0,02 0 -82 173 0 -82G04 UROLOGICALS 50,29 2 2 41 728 2 -9



G04B UROLOGICALS 18,22 1 -1 20 914 2 -18G04BD Drugs for urinary frequency and incontinence 6,80 2 -5 12 348 2 -3G04BD04 oxybutynin 0,16 2 -17 217 2 -24G04BD07 tolterodine 0,28 3 -15 378 4 -17G04BD08 solifenacin 1,51 2 -10 2 340 2 -11G04BD09 trospium 0,21 1 -11 229 1 -11G04BD10 darifenacin 0,06 3 -12 84 4 -11G04BD11 fesoterodine 0,55 2 -55 841 2 -56G04BD12 mirabegron 4,02 2 17 8 259 2 17G04BE Drugs used in erectile dysfunction 8,11 0 4 7 451 1 -37G04BE01 alprostadil 0,06 0 -2 825 1 -3G04BE03 sildenafil 7,38 0 4 1 743 3 -56G04BE08 tadalafil 0,65 0 7 4 621 0 -31G04BE09 vardenafil 0,01 0 -25 128 0 -31G04BE10 avanafil 0,01 0 -29 71 0 -29G04BE30 combinations 0,00 2 - 62 2 176G04BX Other urologicals 3,32 3 -5 1 115 2 -5G04BX01 magnesium hydroxide 3,31 3 -5 1 071 2 -5G04BX14 dapoxetine 0,01 0 -1 45 0 -2G04C DRUGS USED IN BENIGN PROSTATIC 32,07 2 4 20 814 2 2

HYPERTROPHYG04CA Alpha-adrenoreceptor antagonists 22,78 2 5 14 689 1 6G04CA01 alfuzosin 5,60 1 4 2 527 1 6G04CA02 tamsulosin 11,27 2 3 3 449 2 1G04CA52 tamsulosin and dutasteride 5,89 1 10 8 631 1 9G04CA53 tamsulosin and solifenacin 0,02 1 - 82 1 -4G04CB Testosterone-5-alpha reductase inhibitors 8,44 2 1 5 508 2 -9G04CB01 finasteride 6,39 2 -2 4 805 2 2G04CB02 dutasteride 2,05 3 8 702 3 -46G04CX Other drugs used in benign prostatic hypertrophy 0,85 0 15 618 0 13G04CX02 sabalis serrulatae fructus 0,85 0 15 618 0 13H SYSTEMIC HORMONAL PREPARATIONS, 55,91 6 4 47 033 20 3

EXCL. SEX HORMONES AND INSULINSH01 PITUITARY, HYPOTHALAMIC HORMONES AND 1,07 4 23 26 788 10 4

ANALOGUES



H01A ANTERIOR PITUITARY LOBE HORMONES AND 0,17 1 2 8 914 14 0ANALOGUES

H01AB Thyrotrophin 0,00 100 5 1 238 100 5H01AB01 thyrotrophin alfa 0,00 100 5 1 238 100 5H01AC Somatropin and somatropin agonists 0,17 0 4 7 235 0 4H01AC01 somatropin 0,17 0 4 7 235 0 4H01AX Other anterior pituitary hormones and analogues 0,00 1 -40 441 1 -40H01AX01 pegvisomant 0,00 1 -40 441 1 -40H01B POSTERIOR PITUITARY LOBE HORMONES 0,62 5 39 2 440 25 0H01BA Vasopressin and analogues 0,60 2 42 2 250 19 3H01BA02 desmopressin 0,60 2 42 1 932 5 2H01BA04 terlipressin 0,00 100 -3 318 100 13H01BB Oxytocin and analogues 0,02 100 -20 190 100 -30H01BB02 oxytocin 0,02 100 -21 177 100 -33H01BB03 carbetocin 0,00 100 115 13 100 209H01C HYPOTHALAMIC HORMONES 0,27 3 9 15 434 4 7H01CA Gonadotrophin-releasing hormones 0,04 0 21 232 0 21H01CA02 nafarelin 0,04 0 21 232 0 21H01CB Somatostatin and analogues 0,22 3 13 14 763 5 13H01CB02 octreotide 0,12 6 7 7 797 8 7H01CB03 lanreotide 0,10 1 20 6 921 1 20H01CB05 pasireotide 0,00 0 64 45 0 64H01CC Anti gonadotropin releasing hormones 0,01 0 -48 439 0 -62H01CC01 ganirelix 0,01 0 -42 376 0 -59H01CC02 cetrorelix 0,00 0 -71 62 0 -72H02 CORTICOSTEROIDS FOR SYSTEMIC USE 18,92 16 3 10 538 57 0H02A CORTICOSTEROIDS FOR SYSTEMIC USE, 18,82 15 3 8 303 54 4

PLAINH02AA Mineralocorticoids 0,69 7 3 154 7 3H02AA02 fludrocortisone 0,69 7 3 154 7 3H02AB Glucocorticoids 18,14 16 3 8 149 55 4H02AB01 betamethasone 0,17 95 -18 216 87 -2H02AB02 dexamethasone 2,18 40 1 1 544 78 2H02AB04 methylprednisolone 1,16 40 2 1 941 74 -6



H02AB06 prednisolone 12,25 8 3 1 540 20 10H02AB07 prednisone 0,86 8 -11 132 7 -12H02AB08 triamcinolone 0,09 76 -2 878 75 -2H02AB09 hydrocortisone 1,41 15 16 1 898 35 20H02B CORTICOSTEROIDS FOR SYSTEMIC USE, 0,09 69 -12 2 235 69 -12

COMBINATIONSH02BX Corticosteroids for systemic use, combinations 0,09 69 -12 2 235 69 -12H02BX01 methylprednisolone, combinations 0,09 69 -12 2 235 69 -12H03 THYROID THERAPY 35,68 1 5 6 875 2 5H03A THYROID PREPARATIONS 35,10 1 5 6 166 1 5H03AA Thyroid hormones 35,10 1 5 6 166 1 5H03AA01 levothyroxine sodium 35,10 1 5 6 166 1 5H03B ANTITHYROID PREPARATIONS 0,59 5 0 709 5 0H03BB Sulphur-containing imidazole derivatives 0,59 5 0 709 5 0H03BB01 carbimazole 0,59 5 0 709 5 0H04 PANCREATIC HORMONES 0,01 69 7 251 65 6H04A GLYCOGENOLYTIC HORMONES 0,01 69 7 251 65 6H04AA Glycogenolytic hormones 0,01 69 7 251 65 6H04AA01 glucagon 0,01 69 7 251 65 6H05 CALCIUM HOMEOSTASIS 0,23 11 7 2 580 13 0H05A PARATHYROID HORMONES AND ANALOGUES 0,06 5 1 1 343 5 1H05AA Parathyroid hormones and analogues 0,06 5 1 1 343 5 1H05AA02 teriparatide 0,06 5 1 1 343 5 1H05B ANTI-PARATHYROID AGENTS 0,17 13 9 1 237 22 -1H05BA Calcitonin preparations 0,00 98 53 99 98 641H05BA01 calcitonin (salmon synthetic) 0,00 98 53 99 98 641H05BX Other anti-parathyroid agents 0,17 12 9 1 137 16 -8H05BX01 cinacalcet 0,15 7 15 983 10 -7H05BX02 paricalcitol 0,02 45 -21 144 49 -19H05BX04 etelcalcetide 0,00 100 60 10 100 60J ANTIINFECTIVES FOR SYSTEMIC USE 19,13 19 -6 246 844 74 0J01 ANTIBACTERIALS FOR SYSTEMIC USE 16,90 14 -5 49 940 50 -12J01A TETRACYCLINES 3,20 5 -7 2 404 32 -7J01AA Tetracyclines 3,20 5 -7 2 404 32 -7



J01AA02 doxycycline 2,03 7 -6 1 203 18 -3J01AA04 lymecycline 0,77 1 -5 463 1 -5J01AA07 tetracycline 0,40 2 -12 189 2 -12J01AA12 tigecycline 0,00 98 -19 550 98 -15J01C BETA-LACTAM ANTIBACTERIALS, PENICILLINS 6,37 11 -6 17 162 45 -11J01CA Penicillins with extended spectrum 3,61 8 -3 7 216 19 0J01CA01 ampicillin 0,02 100 -17 959 100 4J01CA04 amoxicillin 2,93 7 -3 4 689 6 -1J01CA08 pivmecillinam 0,66 9 -3 1 567 7 -2J01CE Beta-lactamase sensitive penicillins 1,29 8 4 2 133 55 32J01CE01 benzylpenicillin 0,06 99 48 1 152 100 62J01CE02 phenoxymethylpenicillin 1,23 4 2 981 3 8J01CF Beta-lactamase resistant penicillins 0,17 56 11 881 63 18J01CF02 cloxacillin 0,09 97 0 534 97 12J01CF05 flucloxacillin 0,08 10 27 347 10 29J01CR Combinations of penicillins, incl. beta-lactamase 1,30 14 -22 6 932 66 -28

inhibitorsJ01CR02 amoxicillin and beta-lactamase inhibitor 1,23 9 -22 2 486 7 -17J01CR05 piperacillin and beta-lactamase inhibitor 0,07 100 -19 4 446 100 -32J01D OTHER BETA-LACTAM ANTIBACTERIALS 2,92 34 4 14 827 62 -15J01DB First-generation cephalosporins 2,00 6 -1 5 774 5 0J01DB01 cefalexin 2,00 6 -1 5 771 5 0J01DB04 cefazolin 0,00 100 1 286 3 100 1 382J01DC Second-generation cephalosporins 0,77 96 29 4 629 98 -3J01DC02 cefuroxime 0,77 96 29 4 627 98 -3J01DC04 cefaclor 0,00 0 -82 2 0 -82J01DD Third-generation cephalosporins 0,07 97 -22 1 321 93 -8J01DD01 cefotaxime 0,00 99 92 3 93 -61J01DD02 ceftazidime 0,01 100 5 187 100 -34J01DD04 ceftriaxone 0,07 96 -24 1 010 93 -9J01DD52 ceftazidime and beta-lactamase inhibitor 0,00 91 320 121 91 320J01DE Fourth-generation cephalosporins 0,00 100 450 4 100 148J01DE01 cefepime 0,00 100 450 4 100 148J01DF Monobactams 0,00 100 -6 43 100 -6



J01DF01 aztreonam 0,00 100 -6 43 100 -6J01DH Carbapenems 0,07 99 -26 2 750 99 -45J01DH02 meropenem 0,06 99 -7 1 640 99 -17J01DH03 ertapenem 0,01 100 -63 1 111 100 -63J01DI Other cephalosporins and penems 0,00 100 -23 306 100 -35J01DI02 ceftaroline fosamil 0,00 100 103 77 100 103J01DI54 ceftolozane and beta-lactamase inhibitor 0,00 100 -47 229 100 -47J01E SULFONAMIDES AND TRIMETHOPRIM 1,09 8 -10 1 477 10 -6J01EA Trimethoprim and derivatives 0,74 6 -4 818 6 -2J01EA01 trimethoprim 0,74 6 -4 818 6 -2J01EE Combinations of sulfonamides and trimethoprim, 0,35 12 -20 659 14 -11

incl. derivativesJ01EE01 sulfamethoxazole and trimethoprim 0,14 16 -35 162 40 -23J01EE02 sulfadiazine and trimethoprim 0,21 9 -6 498 6 -6J01F MACROLIDES, LINCOSAMIDES AND 0,83 16 -7 3 764 35 -20

STREPTOGRAMINSJ01FA Macrolides 0,55 12 -8 1 662 23 -17J01FA01 erythromycin 0,00 99 26 79 99 23J01FA06 roxithromycin 0,10 9 -3 153 8 -17J01FA09 clarithromycin 0,12 15 -17 449 19 -16J01FA10 azithromycin 0,33 12 -3 982 21 -17J01FA15 telithromycin - - -100 0 - -100J01FF Lincosamides 0,28 23 -5 2 102 44 -23J01FF01 clindamycin 0,28 23 -5 2 102 44 -23J01G AMINOGLYCOSIDE ANTIBACTERIALS 0,02 49 15 1 194 51 19J01GB Other aminoglycosides 0,02 49 15 1 194 51 19J01GB01 tobramycin 0,01 40 18 794 27 20J01GB03 gentamicin 0,00 95 0 211 98 22J01GB06 amikacin 0,00 100 15 190 100 16J01M QUINOLONE ANTIBACTERIALS 0,82 25 -8 3 462 43 -14J01MA Fluoroquinolones 0,82 25 -8 3 462 43 -14J01MA01 ofloxacin - - -100 0 - -100J01MA02 ciprofloxacin 0,48 17 -7 1 750 28 -12J01MA12 levofloxacin 0,25 36 -7 1 175 52 -9



J01MA14 moxifloxacin 0,09 37 -13 538 70 -27J01X OTHER ANTIBACTERIALS 1,65 10 -2 5 650 66 -8J01XA Glycopeptide antibacterials 0,03 100 12 1 497 100 26J01XA01 vancomycin 0,03 100 11 1 175 100 22J01XA02 teicoplanin 0,00 100 23 279 100 23J01XA04 dalbavancin 0,00 100 - 43 100 -J01XB Polymyxins 0,00 0 146 119 0 144J01XB01 colistin 0,00 0 146 119 0 144J01XC Steroid antibacterials 0,00 13 -23 12 12 -21J01XC01 fusidic acid 0,00 13 -23 12 12 -21J01XD Imidazole derivatives 0,06 100 19 982 100 -25J01XD01 metronidazole 0,06 100 19 982 100 -25J01XE Nitrofuran derivatives 0,35 4 -24 605 3 -15J01XE01 nitrofurantoin 0,35 4 -24 605 3 -15J01XX Other antibacterials 1,21 5 5 2 434 51 -16J01XX01 fosfomycin 0,00 100 - 10 100 -J01XX05 methenamine 1,19 4 5 1 030 5 4J01XX08 linezolid 0,01 68 7 824 74 -17J01XX09 daptomycin 0,00 100 -38 568 100 -38J01XX11 tedizolid 0,00 0 - 2 0 -J02 ANTIMYCOTICS FOR SYSTEMIC USE 0,40 16 -6 16 810 76 -28J02A ANTIMYCOTICS FOR SYSTEMIC USE 0,40 16 -6 16 810 76 -28J02AA Antibiotics 0,01 100 -2 2 359 100 -3J02AA01 amphotericin 0,01 100 -2 2 359 100 -3J02AB Imidazole derivatives 0,00 100 -67 1 100 -67J02AB02 ketoconazole 0,00 100 -67 1 100 -67J02AC Triazole derivatives 0,38 12 -5 5 245 23 -25J02AC01 fluconazole 0,27 15 -4 2 844 12 -13J02AC02 itraconazole 0,10 2 0 392 3 -4J02AC03 voriconazole 0,01 24 -34 796 46 -50J02AC04 posaconazole 0,00 48 -46 873 48 -46J02AC05 isavuconazole 0,00 19 258 341 27 246J02AX Other antimycotics for systemic use 0,01 100 -35 9 205 100 -34J02AX04 caspofungin 0,00 100 -53 3 458 100 -54



J02AX05 micafungin 0,00 100 34 3 934 100 33J02AX06 anidulafungin 0,00 100 -48 1 814 100 -48J04 ANTIMYCOBACTERIALS 0,18 86 -4 1 071 90 18J04A DRUGS FOR TREATMENT OF TUBERCULOSIS 0,18 86 -4 1 071 90 18J04AA Aminosalicylic acid and derivatives 0,00 100 -43 24 100 -43J04AA01 aminosalicylic acid 0,00 100 -43 24 100 -43J04AB Antibiotics 0,09 74 20 444 76 17J04AB02 rifampicin 0,09 73 22 377 73 22J04AB04 rifabutin 0,01 90 -6 68 90 -7J04AC Hydrazides 0,04 98 -30 84 98 -26J04AC01 isoniazid 0,04 98 -30 84 98 -26J04AK Other drugs for treatment of tuberculosis 0,04 100 -10 518 100 41J04AK01 pyrazinamide 0,02 100 -12 72 100 -10J04AK02 ethambutol 0,03 100 -12 191 100 -12J04AK05 bedaquiline 0,00 100 267 255 100 267J05 ANTIVIRALS FOR SYSTEMIC USE 1,65 59 -15 113 142 93 25J05A DIRECT ACTING ANTIVIRALS 1,65 59 -15 113 142 93 25J05AB Nucleosides and nucleotides excl. reverse 0,63 8 8 10 645 38 6

transcriptase inhibitorsJ05AB01 aciclovir 0,27 4 5 2 703 24 -6J05AB06 ganciclovir 0,00 100 -27 168 100 -41J05AB09 famciclovir 0,01 3 31 137 5 33J05AB11 valaciclovir 0,32 3 9 4 543 3 10J05AB14 valganciclovir 0,03 100 35 3 094 100 20J05AE Protease inhibitors 0,06 100 -27 2 652 100 -30J05AE01 saquinavir 0,00 100 -48 12 100 -49J05AE03 ritonavir 0,01 100 -55 198 100 -60J05AE07 fosamprenavir 0,00 100 -86 6 100 -86J05AE08 atazanavir 0,02 100 -23 669 100 -34J05AE10 darunavir 0,03 100 -17 1 767 100 -20J05AF Nucleoside and nucleotide reverse transcriptase 0,07 99 -28 1 181 99 -45

inhibitorsJ05AF01 zidovudine 0,00 100 0 14 100 0J05AF05 lamivudine 0,01 98 -58 77 98 -58



J05AF06 abacavir 0,00 100 -65 81 100 -65J05AF07 tenofovir disoproxil 0,04 100 -15 639 100 -51J05AF08 adefovir dipivoxil 0,00 100 -52 32 100 -52J05AF09 emtricitabine 0,00 100 -58 9 100 -58J05AF10 entecavir 0,00 95 17 118 96 8J05AF13 tenofovir alafenamide 0,01 100 -6 211 100 -6J05AG Non-nucleoside reverse transcriptase inhibitors 0,05 100 -1 963 100 -8J05AG01 nevirapine 0,02 100 -8 496 100 -8J05AG03 efavirenz 0,01 100 14 115 100 -15J05AG04 etravirine 0,01 100 -20 202 100 -20J05AG05 rilpivirine 0,01 100 28 151 100 28J05AH Neuraminidase inhibitors 0,14 32 20 1 409 32 15J05AH01 zanamivir - - -100 0 - -100J05AH02 oseltamivir 0,14 32 20 1 409 32 15J05AP Antivirals for treatment of HCV infections 0,07 100 34 64 610 100 191J05AP01 ribavirin 0,01 100 -64 545 100 -64J05AP05 simeprevir - - -100 0 - -100J05AP08 sofosbuvir 0,00 100 -95 42 100 -95J05AP09 dasabuvir 0,00 100 -98 1 100 -98J05AP51 sofosbuvir and ledipasvir 0,00 100 -79 312 100 -79J05AP53 ombitasvir, paritaprevir and ritonavir 0,00 100 -98 14 100 -98J05AP54 elbasvir and grazoprevir 0,02 100 182 22 937 100 183J05AP55 sofosbuvir and velpatasvir 0,03 100 416 40 246 100 416J05AP56 sofosbuvir, velpatasvir and voxilaprevir 0,00 100 - 108 100 -J05AP57 glecaprevir and pibrentasvir 0,00 100 -76 406 100 -76J05AR Antivirals for treatment of HIV infections, 0,45 100 -36 24 398 100 -38

combinationsJ05AR01 zidovudine and lamivudine 0,00 96 -44 23 97 -59J05AR02 lamivudine and abacavir 0,04 100 -41 792 100 -68J05AR03 tenofovir disoproxil and emtricitabine 0,06 100 68 2 757 100 74J05AR04 zidovudine, lamivudine and abacavir 0,00 100 -58 11 100 -58J05AR06 emtricitabine, tenofovir disoproxil and efavirenz 0,02 100 -49 1 249 100 -50J05AR08 emtricitabine, tenofovir disoproxil and rilpivirine 0,00 97 -56 203 97 -55J05AR09 emtricitabine, tenofovir disoproxil, elvitegravir and 0,00 100 -66 205 100 -69

cobicistat



J05AR10 lopinavir and ritonavir 0,00 100 -57 138 100 -62J05AR13 lamivudine, abacavir and dolutegravir 0,09 100 -46 6 992 100 -47J05AR14 darunavir and cobicistat 0,00 100 48 177 100 48J05AR17 emtricitabine and tenofovir alafenamide 0,13 100 -46 5 171 100 -48J05AR18 emtricitabine, tenofovir alafenamide, elvitegravir 0,04 100 -31 3 136 100 -37

and cobicistatJ05AR19 emtricitabine, tenofovir alafenamide and rilpivirine 0,03 100 -26 2 050 100 -29J05AR20 emtricitabine, tenofovir alafenamide and bictegravir - - - 942 100 -J05AR21 dolutegravir and rilpivirine - - - 59 100 -J05AR22 emtricitabine, tenofovir alafenamide, darunavir 0,01 100 2 218 495 100 2 218

and cobicistatJ05AX Other antivirals 0,19 100 -28 7 285 100 -32J05AX07 enfuvirtide 0,00 100 -93 2 100 -93J05AX08 raltegravir 0,07 100 -34 2 195 100 -45J05AX09 maraviroc 0,00 100 -42 75 100 -45J05AX12 dolutegravir 0,12 100 -23 5 012 100 -24J06 IMMUNE SERA AND IMMUNOGLOBULINS - - - 40 633 81 -6J06B IMMUNOGLOBULINS - - - 40 633 81 -6J06BA Immunoglobulins, normal human - - - 39 068 80 -4J06BA01 immunoglobulins, normal human, for extravascular - - - 7 852 3 11

adm.J06BA02 immunoglobulins, normal human, for intravascular - - - 31 217 100 -7

adm.J06BB Specific immunoglobulins - - - 1 565 100 -37J06BB01 anti-D (rh) immunoglobulin - - - 618 100 -9J06BB16 palivizumab - - - 793 100 -43J06BB21 bezlotoxumab - - - 153 100 -63J07 VACCINES - - - 25 248 18 -22J07A BACTERIAL VACCINES - - - 6 403 46 -50J07AE Cholera vaccines - - - 140 12 9J07AE01 cholera, inactivated, whole cell - - - 140 12 9J07AG Haemophilus influenzae B vaccines - - - 3 94 -J07AG01 haemophilus influenzae B, purified antigen - - - 3 94 -

conjugated



J07AH Meningococcal vaccines - - - 847 80 -80J07AH07 meningococcus C, purified polysaccharides - - - 0 - -100

antigen conjugatedJ07AH08 meningococcus A, C, Y, W-135, tetravalent - - - 829 81 -80

purified polysaccharides antigen conjugatedJ07AH09 meningococcus B, multicomponent vaccine - - - 17 20 539J07AJ Pertussis vaccines - - - 259 3 -27J07AJ52 pertussis, purified antigen, combinations with - - - 259 3 -27

toxoidsJ07AL Pneumococcal vaccines - - - 4 669 47 -41J07AL01 pneumococcus, purified polysaccharides antigen - - - 83 18 -27J07AL02 pneumococcus, purified polysaccharides antigen - - - 4 586 48 -41

conjugatedJ07AM Tetanus vaccines - - - 283 1 170J07AM51 tetanus toxoid, combinations with diphtheria toxoid - - - 283 1 170J07AP Typhoid vaccines - - - 202 5 -16J07AP01 typhoid, oral, live attenuated - - - 143 3 -35J07AP03 typhoid, purified polysaccharide antigen - - - 59 12 190J07B VIRAL VACCINES - - - 18 818 9 -4J07BA Encephalitis vaccines - - - 5 792 15 -19J07BA01 encephalitis, tick borne, inactivated, whole virus - - - 5 226 16 -14J07BA02 encephalitis, Japanese, inactivated, whole virus - - - 567 1 -47J07BB Influenza vaccines - - - 2 685 2 28J07BB02 influenza, purified antigen - - - 2 587 2 30J07BB03 influenza, live attenuated - - - 98 0 -16J07BC Hepatitis vaccines - - - 9 194 8 1J07BC01 hepatitis B, purified antigen - - - 1 410 26 1J07BC02 hepatitis A, inactivated, whole virus - - - 1 309 6 -8J07BC20 combinations - - - 6 475 4 3J07BD Measles vaccines - - - 122 0 99J07BD52 measles, combinations with mumps and rubella, - - - 122 0 99

live attenuatedJ07BF Poliomyelitis vaccines - - - 26 31 -43J07BF03 poliomyelitis, trivalent, inactivated, whole virus - - - 26 31 -43



J07BH Rota virus diarrhea vaccines - - - 3 0 -40J07BH02 rota virus, pentavalent, live, reassorted - - - 3 0 -40J07BK Varicella zoster vaccines - - - 420 3 -24J07BK01 varicella, live attenuated - - - 288 5 -35J07BK02 zoster, live attenuated - - - 132 1 17J07BL Yellow fever vaccines - - - 383 4 0J07BL01 yellow fever, live attenuated - - - 383 4 0J07BM Papillomavirus vaccines - - - 192 6 95J07BM01 papillomavirus (human types 6, 11, 16, 18) - - - 0 - -100J07BM03 ppapillomavirus (human types 6, 11, 16, 18, 31, - - - 192 6 335

33, 45, 52, 58)J07C BACTERIAL AND VIRAL VACCINES, COMBINED - - - 27 1 196J07CA Bacterial and viral vaccines, combined - - - 27 1 196J07CA02 diphtheria, pertussis, poliomyelitis, tetanus - - - 13 1 155J07CA06 diphtheria, Haemophilus influenzae B, pertussis, - - - 5 0 23

poliomyelitis, tetanusJ07CA10 typhoid - hepatitis A - - - 9 0 -L ANTINEOPLASTIC AND 22,15 10 -5 686 484 44 -10

IMMUNOMODULATING AGENTSL01 ANTINEOPLASTIC AGENTS - - - 261 196 75 1L01A ALKYLATING AGENTS - - - 4 937 65 -12L01AA Nitrogen mustard analogues - - - 2 544 94 -22L01AA01 cyclophosphamide - - - 816 96 -9L01AA02 chlorambucil - - - 113 16 40L01AA03 melphalan - - - 63 39 -13L01AA06 ifosfamide - - - 407 100 2L01AA09 bendamustine - - - 1 143 100 -37L01AB Alkyl sulphonates - - - 119 100 -11L01AB01 busulfan - - - 119 100 -11L01AC Ethylene imines - - - 421 100 35L01AC01 thiotepa - - - 421 100 35L01AD Nitrosoureas - - - 42 99 44L01AD01 carmustine - - - 13 100 -L01AD02 lomustine - - - 29 99 0



L01AX Other alkylating agents - - - 1 812 13 -2L01AX03 temozolomide - - - 1 693 7 0L01AX04 dacarbazine - - - 118 100 -26L01B ANTIMETABOLITES - - - 18 147 83 -17L01BA Folic acid analogues - - - 6 942 98 0L01BA01 methotrexate - - - 636 73 -26L01BA04 pemetrexed - - - 6 306 100 4L01BB Purine analogues - - - 1 395 27 170L01BB02 mercaptopurine - - - 97 18 76L01BB04 cladribine - - - 1 014 14 722L01BB05 fludarabine - - - 176 60 -6L01BB06 clofarabine - - - 107 100 -6L01BB07 nelarabine - - - 0 - -100L01BC Pyrimidine analogues - - - 9 810 81 -32L01BC01 cytarabine - - - 212 100 -5L01BC02 fluorouracil - - - 374 100 194L01BC05 gemcitabine - - - 1 147 100 129L01BC06 capecitabine - - - 1 221 2 -11L01BC07 azacitidine - - - 5 935 100 -50L01BC08 decitabine - - - 231 100 918L01BC52 fluorouracil, combinations - - - 1 0 -8L01BC53 tegafur, combinations - - - 144 6 -59L01BC59 trifluridine, combinations - - - 545 1 2 014L01C PLANT ALKALOIDS AND OTHER NATURAL - - - 12 949 90 -6

PRODUCTSL01CA Vinca alkaloids and analogues - - - 1 824 37 1L01CA01 vinblastine - - - 27 100 16L01CA02 vincristine - - - 140 100 -20L01CA03 vindesine - - - 5 100 -8L01CA04 vinorelbine - - - 1 521 25 10L01CA05 vinflunine - - - 132 100 -38L01CB Podophyllotoxin derivatives - - - 336 72 26L01CB01 etoposide - - - 336 72 26L01CD Taxanes - - - 10 145 100 -8



L01CD01 paclitaxel - - - 5 872 100 -14L01CD02 docetaxel - - - 890 100 9L01CD04 cabazitaxel - - - 3 383 100 -1L01CX Other plant alkaloids and other natural products - - - 644 100 -6L01CX01 trabectedin - - - 644 100 -6L01D CYTOTOXIC ANTIBIOTICS AND RELATED - - - 4 308 99 -12

SUBSTANCESL01DB Anthracyclines and related substances - - - 3 848 100 -12L01DB01 doxorubicin - - - 1 933 100 -4L01DB03 epirubicin - - - 1 343 100 -26L01DB06 idarubicin - - - 329 100 -22L01DB07 mitoxantrone - - - 162 100 32L01DB11 pixantrone - - - 82 100 1 350L01DC Other cytotoxic antibiotics - - - 460 96 -16L01DC01 bleomycin - - - 73 100 7L01DC03 mitomycin - - - 387 95 -19L01X OTHER ANTINEOPLASTIC AGENTS - - - 220 856 73 4L01XA Platinum compounds - - - 1 223 100 94L01XA01 cisplatin - - - 234 100 263L01XA02 carboplatin - - - 326 99 3L01XA03 oxaliplatin - - - 662 100 163L01XC Monoclonal antibodies - - - 131 780 100 7L01XC02 rituximab - - - 35 153 100 0L01XC03 trastuzumab - - - 26 036 100 5L01XC05 gemtuzumab ozogamicin - - - 14 100 -L01XC06 cetuximab - - - 2 580 100 21L01XC07 bevacizumab - - - 24 275 100 9L01XC08 panitumumab - - - 4 403 100 6L01XC10 ofatumumab - - - 222 100 79L01XC11 ipilimumab - - - 170 100 225L01XC12 brentuximab vedotin - - - 921 100 -66L01XC13 pertuzumab - - - 9 767 100 23L01XC14 trastuzumab emtansine - - - 3 734 100 -6L01XC15 obinutuzumab - - - 1 349 100 -58



L01XC17 nivolumab - - - 8 200 100 46L01XC18 pembrolizumab - - - 6 365 100 -13L01XC19 blinatumomab - - - 363 100 -79L01XC21 ramucirumab - - - 317 100 112L01XC22 necitumumab - - - 6 100 0L01XC23 elotuzumab - - - 63 100 -L01XC24 daratumumab - - - 5 383 100 193L01XC26 inotuzumab ozogamicin - - - 339 100 42L01XC27 olaratumab - - - 1 308 100 343L01XC32 atezolizumab - - - 813 100 2 517L01XD Sensitizers used in photodynamic/radiation therapy - - - 935 100 3L01XD03 methyl aminolevulinate - - - 698 100 5L01XD04 aminolevulinic acid - - - 237 100 -2L01XE Protein kinase inhibitors - - - 57 737 5 1L01XE01 imatinib - - - 5 977 1 -14L01XE02 gefitinib - - - 904 4 -46L01XE03 erlotinib - - - 1 521 3 -27L01XE04 sunitinib - - - 5 886 2 -44L01XE05 sorafenib - - - 2 217 13 -21L01XE06 dasatinib - - - 2 621 5 -13L01XE07 lapatinib - - - 618 1 2L01XE08 nilotinib - - - 2 505 1 6L01XE09 temsirolimus - - - 34 100 -74L01XE10 everolimus - - - 1 976 6 11L01XE11 pazopanib - - - 2 889 1 -1L01XE12 vandetanib - - - 145 100 18L01XE13 afatinib - - - 1 106 2 32L01XE14 bosutinib - - - 436 2 -13L01XE15 vemurafenib - - - 631 2 -66L01XE16 crizotinib - - - 1 540 5 -25L01XE17 axitinib - - - 1 661 0 -51L01XE18 ruxolitinib - - - 3 818 12 29L01XE21 regorafenib - - - 1 369 0 -45L01XE23 dabrafenib - - - 5 147 1 8



L01XE24 ponatinib - - - 718 18 41L01XE25 trametinib - - - 1 976 2 -L01XE26 cabozantinib - - - 1 827 1 4 514L01XE27 ibrutinib - - - 4 413 5 -L01XE28 ceritinib - - - 0 - -100L01XE29 lenvatinib - - - 375 0 347L01XE31 nintedanib - - - 3 238 1 55L01XE33 palbociclib - - - 1 141 1 729L01XE35 osimertinib - - - 396 62 79L01XE36 alectinib - - - 41 28 -L01XE39 midostaurin - - - 610 100 -L01XX Other antineoplastic agents - - - 29 182 83 -5L01XX05 hydroxycarbamide - - - 468 2 0L01XX11 estramustine - - - 6 2 -71L01XX14 tretinoin - - - 49 99 -4L01XX17 topotecan - - - 156 37 -14L01XX19 irinotecan - - - 653 100 -52L01XX23 mitotane - - - 256 4 28L01XX24 pegaspargase - - - 630 99 13L01XX25 bexarotene - - - 362 100 -41L01XX27 arsenic trioxide - - - 172 100 11L01XX32 bortezomib - - - 11 412 100 4L01XX35 anagrelide - - - 677 1 -73L01XX41 eribulin - - - 1 182 100 -27L01XX43 vismodegib - - - 258 5 -24L01XX44 aflibercept - - - 509 100 -27L01XX45 carfilzomib - - - 8 673 100 47L01XX46 olaparib - - - 713 1 3 422L01XX47 idelalisib - - - 2 351 4 -53L01XX50 ixazomib - - - 450 71 145L01XX51 talimogene laherparepvec - - - 0 - -100L01XX52 venetoclax - - - 207 49 -L02 ENDOCRINE THERAPY 7,60 3 2 55 959 3 38L02A HORMONES AND RELATED AGENTS 1,72 4 2 11 781 5 0



L02AB Progestogens 0,01 7 6 101 7 6L02AB02 medroxyprogesterone 0,01 7 6 101 7 6L02AE Gonadotrophin releasing hormone analogues 1,70 4 2 11 680 5 0L02AE01 buserelin 0,00 0 -19 28 0 -16L02AE02 leuprorelin 1,33 5 -1 9 074 5 -2L02AE03 goserelin 0,20 5 -16 1 409 5 -19L02AE04 triptorelin 0,17 3 96 1 170 3 75L02B HORMONE ANTAGONISTS AND RELATED 5,89 3 3 44 178 2 54

AGENTSL02BA Anti-estrogens 1,20 2 1 2 946 5 4L02BA01 tamoxifen 1,07 1 1 551 1 1L02BA02 toremifene 0,01 1 -5 12 1 -5L02BA03 fulvestrant 0,13 6 6 2 384 6 5L02BB Anti-androgens 1,73 2 1 27 317 1 94L02BB01 flutamide 0,01 5 -36 36 5 -36L02BB03 bicalutamide 1,59 2 -3 1 373 2 -7L02BB04 enzalutamide 0,13 1 107 25 909 1 107L02BG Aromatase inhibitors 2,65 2 5 1 166 2 14L02BG03 anastrozole 0,27 2 -24 173 2 -2L02BG04 letrozole 2,15 2 8 828 1 18L02BG06 exemestane 0,24 3 21 165 3 14L02BX Other hormone antagonists and related agents 0,31 19 2 12 748 4 18L02BX02 degarelix 0,26 23 -1 1 969 17 -2L02BX03 abiraterone 0,05 1 22 10 779 1 22L03 IMMUNOSTIMULANTS 0,76 5 -50 37 862 14 -42L03A IMMUNOSTIMULANTS 0,76 5 -50 37 862 14 -42L03AA Colony stimulating factors 0,23 15 -29 19 383 16 -28L03AA02 filgrastim 0,03 35 -37 3 247 39 -41L03AA10 lenograstim 0,00 33 -2 28 33 -2L03AA13 pegfilgrastim 0,11 15 12 9 330 15 12L03AA14 lipegfilgrastim 0,09 7 -48 6 777 7 -48L03AB Interferons 0,43 1 -56 10 496 2 -56L03AB04 interferon alfa-2a 0,01 1 -5 205 1 -5L03AB05 interferon alfa-2b 0,03 1 -54 778 1 -54



L03AB07 interferon beta-1a 0,32 0 -58 6 762 0 -58L03AB08 interferon beta-1b 0,03 0 -19 1 050 0 -24L03AB10 peginterferon alfa-2b 0,00 100 -92 21 100 -92L03AB11 peginterferon alfa-2a 0,00 100 -92 140 100 -92L03AB13 peginterferon beta-1a 0,03 0 -26 1 540 0 -27L03AX Other immunostimulants 0,11 0 -54 7 983 24 -46L03AX03 BCG vaccine - - - 714 99 4L03AX13 glatiramer acetate 0,11 0 -54 6 105 0 -55L03AX16 plerixafor 0,00 100 57 1 165 100 57L04 IMMUNOSUPPRESSANTS 13,78 15 -4 331 467 30 -17L04A IMMUNOSUPPRESSANTS 13,78 15 -4 331 467 30 -17L04AA Selective immunosuppressants 1,53 14 5 57 855 35 20L04AA04 antithymocyte immunoglobulin 0,00 100 1 249 100 1L04AA06 mycophenolic acid 0,45 4 2 4 577 5 2L04AA10 sirolimus 0,01 18 -46 159 18 -47L04AA13 leflunomide 0,49 2 -7 379 2 -18L04AA18 everolimus 0,00 94 12 89 94 12L04AA24 abatacept 0,08 42 8 7 914 36 8L04AA26 belimumab 0,00 100 -29 379 100 -33L04AA27 fingolimod 0,14 0 16 14 370 0 13L04AA29 tofacitinib 0,04 3 401 2 357 3 393L04AA31 teriflunomide 0,12 0 14 6 544 0 10L04AA32 apremilast 0,04 0 -26 2 257 0 -26L04AA33 vedolizumab 0,13 100 49 13 688 100 49L04AA34 alemtuzumab 0,01 97 -68 985 97 -68L04AA36 ocrelizumab 0,01 100 - 1 700 100 -L04AA37 baricitinib 0,02 1 - 2 208 2 1 994L04AB Tumor necrosis factor alpha (TNF-a) inhibitors 3,41 46 -24 172 902 39 -23L04AB01 etanercept 0,56 0 -35 26 327 0 -52L04AB02 infliximab 1,53 100 -13 66 381 100 22L04AB04 adalimumab 0,77 2 -41 51 988 2 -41L04AB05 certolizumab pegol 0,10 2 18 6 206 2 17L04AB06 golimumab 0,45 1 -7 22 001 1 0L04AC Interleukin inhibitors 0,65 23 37 34 078 21 31



L04AC01 daclizumab 0,00 0 -71 14 0 -73L04AC02 basiliximab 0,00 100 23 256 100 20L04AC03 anakinra 0,01 11 3 466 11 3L04AC05 ustekinumab 0,33 24 45 12 005 17 33L04AC07 tocilizumab 0,14 49 13 9 001 54 12L04AC10 secukinumab 0,14 0 32 9 818 0 32L04AC12 brodalumab - - - 14 0 -L04AC13 ixekizumab 0,03 0 147 1 923 0 146L04AC14 sarilumab 0,00 0 - 197 0 -L04AC16 guselkumab 0,00 0 - 382 0 -L04AD Calcineurin inhibitors 0,74 5 8 11 653 5 0L04AD01 ciclosporin 0,40 4 0 4 933 4 -19L04AD02 tacrolimus 0,34 5 19 6 721 6 19L04AX Other immunosuppressants 7,46 1 2 54 979 4 -39L04AX01 azathioprine 1,48 1 6 1 078 1 8L04AX02 thalidomide 0,00 23 -61 101 23 -61L04AX03 methotrexate 5,67 1 7 7 404 0 15L04AX04 lenalidomide 0,09 5 -40 26 653 6 -38L04AX05 pirfenidone 0,03 2 -37 4 277 2 -37L04AX06 pomalidomide 0,00 23 67 1 851 22 117L04AX07 dimethyl fumarate 0,19 0 -56 13 614 0 -57M MUSCULO-SKELETAL SYSTEM 97,15 2 -1 100 847 23 4M01 ANTIINFLAMMATORY AND ANTIRHEUMATIC 77,40 2 0 44 453 2 -9

PRODUCTSM01A ANTIINFLAMMATORY AND ANTIRHEUMATIC 77,28 2 0 44 375 2 -9

PRODUCTS, NON-STEROIDSM01AB Acetic acid derivatives and related substances 4,04 2 -26 2 296 7 -29M01AB01 indometacin 0,19 1 -10 136 1 -3M01AB05 diclofenac 3,76 2 -27 2 002 5 -31M01AB15 ketorolac 0,02 81 -2 65 81 -2M01AB55 diclofenac, combinations 0,07 1 -14 92 1 -13M01AC Oxicams 1,25 1 -14 414 1 -15M01AC06 meloxicam 1,25 1 -14 414 1 -15M01AE Propionic acid derivatives 58,44 2 1 32 985 1 -2



M01AE01 ibuprofen 49,77 1 1 28 767 1 -1M01AE02 naproxen 5,90 2 -2 1 906 2 -9M01AE03 ketoprofen 0,74 1 -8 494 1 -7M01AE17 dexketoprofen 0,04 88 16 193 83 16M01AE51 ibuprofen, combinations 0,48 0 -12 742 0 -9M01AE52 naproxen and esomeprazole 1,51 0 -3 884 0 -3M01AG Fenamates 0,22 2 -7 93 3 -8M01AG01 mefenamic acid 0,04 12 -16 18 17 -16M01AG02 tolfenamic acid 0,18 0 -5 75 0 -5M01AH Coxibs 9,55 1 17 4 013 4 -42M01AH01 celecoxib 0,67 2 -8 240 2 -25M01AH04 parecoxib 0,00 99 -46 50 99 -46M01AH05 etoricoxib 8,89 1 19 3 723 2 -43M01AX Other antiinflammatory and antirheumatic agents, 3,78 1 -11 4 575 1 -2

non-steroidsM01AX01 nabumetone 0,04 1 -11 18 1 -11M01AX05 glucosamine 3,74 1 -11 2 111 1 -9M01AX25 chondroitin sulfate - - - 2 446 0 5M01C SPECIFIC ANTIRHEUMATIC AGENTS 0,12 1 -8 78 1 -8M01CB Gold preparations 0,12 1 -8 78 1 -8M01CB01 sodium aurothiomalate 0,12 1 -8 78 1 -8M02 TOPICAL PRODUCTS FOR JOINT AND - - - 12 945 1 -6

MUSCULAR PAINM02A TOPICAL PRODUCTS FOR JOINT AND - - - 12 945 1 -6

MUSCULAR PAINM02AA Antiinflammatory preparations, non-steroids for - - - 11 958 1 -5

topical useM02AA07 piroxicam - - - 898 3 -7M02AA10 ketoprofen - - - 94 25 -21M02AA13 ibuprofen - - - 616 0 -M02AA15 diclofenac - - - 10 350 0 -10M02AC Preparations with salicylic acid derivatives - - - 987 5 -10M03 MUSCLE RELAXANTS 4,68 3 -10 14 344 63 7M03A MUSCLE RELAXANTS, PERIPHERALLY - - - 10 244 81 9

ACTING AGENTS



M03AB Choline derivatives - - - 637 99 29M03AB01 suxamethonium - - - 637 99 29M03AC Other quaternary ammonium compounds - - - 1 911 99 9M03AC09 rocuronium bromide - - - 1 799 99 10M03AC10 mivacurium chloride - - - 22 93 -12M03AC11 cisatracurium - - - 89 100 -6M03AX Other muscle relaxants, peripherally acting agents - - - 7 697 75 8M03AX01 botulinum toxin - - - 7 697 75 8M03B MUSCLE RELAXANTS, CENTRALLY ACTING 4,68 3 -10 4 100 20 2

AGENTSM03BC Ethers, chemically close to antihistamines 2,25 2 -19 1 078 42 -13M03BC01 orphenadrine (citrate) 2,00 2 -21 953 48 -15M03BC51 orphenadrine, combinations 0,26 1 0 125 1 1M03BX Other centrally acting agents 2,42 3 0 3 022 12 9M03BX01 baclofen 0,51 8 11 818 38 64M03BX02 tizanidine 1,91 2 -2 2 203 2 -3M04 ANTIGOUT PREPARATIONS 3,99 2 8 1 941 3 9M04A ANTIGOUT PREPARATIONS 3,99 2 8 1 941 3 9M04AA Preparations inhibiting uric acid production 3,98 2 8 1 904 2 8M04AA01 allopurinol 3,75 2 7 1 501 2 7M04AA03 febuxostat 0,23 4 18 403 4 13M04AC Preparations with no effect on uric acid metabolism 0,02 15 46 37 15 46M04AC01 colchicine 0,02 15 46 37 15 46M05 DRUGS FOR TREATMENT OF BONE DISEASES 11,01 5 -1 16 114 14 0M05B DRUGS AFFECTING BONE STRUCTURE AND 11,01 5 -1 16 114 14 0

MINERALIZATIONM05BA Bisphosphonates 3,58 2 -5 3 083 44 -11M05BA02 clodronic acid 0,02 1 -27 167 1 -33M05BA03 pamidronic acid 0,00 100 -51 91 100 -51M05BA04 alendronic acid 2,31 2 -3 946 2 2M05BA06 ibandronic acid 0,59 2 -11 261 8 -14M05BA07 risedronic acid 0,66 3 -8 389 4 -4M05BA08 zoledronic acid 0,01 99 -31 1 229 98 -11M05BB Bisphosphonates, combinations 0,22 1 -64 264 1 -64



M05BB03 alendronic acid and colecalciferol 0,22 1 -64 264 1 -64M05BC Bone morphogenetic proteins - - - 40 100 30M05BC01 dibotermin alfa - - - 40 100 30M05BX Other drugs affecting mineralization 7,21 7 7 12 727 6 8M05BX03 strontium ranelate 0,00 100 -100 0 100 -100M05BX04 denosumab 7,21 7 8 12 727 6 8M09 OTHER DRUGS FOR DISORDERS OF THE 0,07 73 -3 11 051 98 244

MUSCULO-SKELETAL SYSTEMM09A OTHER DRUGS FOR DISORDERS OF THE 0,07 73 -3 11 051 98 244

MUSCULO-SKELETAL SYSTEMM09AB Enzymes 0,00 97 4 1 021 97 4M09AB02 collagenase clostridium histolyticum 0,00 97 4 1 021 97 4M09AX Other drugs for disorders of the musculo-skeletal 0,07 73 -3 10 029 98 350

systemM09AX01 hyaluronic acid 0,07 71 -8 613 71 -16M09AX07 nusinersen 0,00 100 - 9 416 100 528N NERVOUS SYSTEM 269,18 8 0 342 599 29 -10N01 ANESTHETICS - - - 19 720 89 2N01A ANESTHETICS, GENERAL - - - 10 396 96 7N01AB Halogenated hydrocarbons - - - 3 136 98 3N01AB06 isoflurane - - - 10 100 9N01AB07 desflurane - - - 698 100 10N01AB08 sevoflurane - - - 2 428 97 2N01AF Barbiturates, plain - - - 108 99 20N01AF03 thiopental - - - 108 99 20N01AH Opioid anesthetics - - - 1 708 95 9N01AH01 fentanyl - - - 222 98 -3N01AH02 alfentanil - - - 167 93 -5N01AH03 sufentanil - - - 37 100 -31N01AH06 remifentanil - - - 1 282 94 15N01AX Other general anesthetics - - - 5 444 96 9N01AX03 ketamine - - - 52 88 57N01AX10 propofol - - - 4 144 96 7N01AX14 esketamine - - - 1 247 96 15



N01B ANESTHETICS, LOCAL - - - 9 324 80 -4N01BB Amides - - - 8 905 80 -4N01BB01 bupivacaine - - - 878 90 -12N01BB02 lidocaine - - - 1 849 81 -18N01BB03 mepivacaine - - - 5 19 -22N01BB09 ropivacaine - - - 1 453 96 10N01BB10 levobupivacaine - - - 983 99 2N01BB20 combinations - - - 1 099 51 1N01BB51 bupivacaine, combinations - - - 39 88 -17N01BB52 lidocaine, combinations - - - 1 082 82 1N01BB54 prilocaine, combinations - - - 145 61 -7N01BB58 articaine, combinations - - - 1 372 67 -1N01BX Other local anesthetics - - - 419 90 -2N01BX04 capsaicin - - - 419 90 -2N02 ANALGESICS 54,50 6 0 63 175 16 -5N02A OPIOIDS 13,91 9 -5 27 304 24 -12N02AA Natural opium alkaloids 2,33 35 0 10 431 50 -5N02AA01 morphine 0,29 84 -7 1 646 86 8N02AA03 hydromorphone 0,09 55 -27 511 63 -33N02AA05 oxycodone 1,68 25 3 4 924 48 -3N02AA55 oxycodone and naloxone 0,27 36 -1 3 349 34 -6N02AB Phenylpiperidine derivatives 0,83 20 -7 3 838 20 -11N02AB03 fentanyl 0,83 20 -7 3 838 20 -11N02AE Oripavine derivatives 1,38 6 8 5 231 6 -26N02AE01 buprenorphine 1,38 6 8 5 231 6 -26N02AJ Opioids in combination with non-opioid analgesics 6,75 1 -9 3 904 1 -15N02AJ06 codeine and paracetamol 6,32 2 -11 3 307 1 -17N02AJ08 codeine and ibuprofen 0,14 0 -13 341 0 -29N02AJ13 tramadol and paracetamol 0,29 1 93 251 1 78N02AJ14 taramadol and dexketoprofen - - - 5 0 338N02AX Other opioids 2,62 2 -5 3 899 4 -6N02AX02 tramadol 2,62 2 -5 3 899 4 -6N02B OTHER ANALGESICS AND ANTIPYRETICS 38,30 5 1 29 358 10 -1N02BA Salicylic acid and derivatives 1,68 0 -10 4 569 0 -8



N02BA01 acetylsalicylic acid 0,83 1 -12 1 142 1 -22N02BA51 acetylsalicylic acid, combinations excl. 0,85 0 -8 3 427 0 -2

psycholepticsN02BE Anilides 36,62 6 2 24 665 12 0N02BE01 paracetamol 36,46 6 2 24 190 12 0N02BE51 paracetamol, combinations excl. psycholeptics 0,16 0 -7 475 0 3N02BG Other analgesics and antipyretics - - - 123 17 29N02BG09 methoxyflurane - - - 2 100 -N02BG10 cannabinoids - - - 121 16 27N02C ANTIMIGRAINE PREPARATIONS 2,29 1 7 6 513 7 15N02CC Selective 5HT1-receptor agonists 2,29 1 7 6 006 1 6N02CC01 sumatriptan 1,49 1 10 2 793 2 21N02CC02 naratriptan 0,02 0 -4 152 0 -7N02CC03 zolmitriptan 0,19 1 -12 817 1 -19N02CC04 rizatriptan 0,13 0 11 645 0 7N02CC05 almotriptan 0,10 0 7 437 0 5N02CC06 eletriptan 0,20 0 11 592 0 0N02CC07 frovatriptan 0,15 0 10 570 0 3N02CX Other antimigraine preparations - - - 507 79 -N02CX07 erenumab - - - 507 79 -N03 ANTIEPILEPTICS 22,23 4 -13 54 748 9 -24N03A ANTIEPILEPTICS 22,23 4 -13 54 748 9 -24N03AB Hydantoin derivatives 0,19 10 -8 907 86 -26N03AB02 phenytoin 0,18 7 -7 138 7 -7N03AB05 fosphenytoin 0,01 100 -29 769 100 -29N03AE Benzodiazepine derivatives 0,74 2 -6 533 3 -5N03AE01 clonazepam 0,74 2 -6 533 3 -5N03AF Carboxamide derivatives 3,66 3 0 4 912 4 1N03AF01 carbamazepine 1,40 3 -3 1 246 9 1N03AF02 oxcarbazepine 2,20 3 2 3 073 3 2N03AF03 rufinamide 0,01 5 -44 204 6 -44N03AF04 eslicarbazepine 0,05 3 43 389 3 41N03AG Fatty acid derivatives 3,57 6 -2 4 795 11 0N03AG01 valproic acid 3,56 6 -2 4 707 11 0



N03AG04 vigabatrin 0,02 10 -3 89 10 -3N03AX Other antiepileptics 14,07 4 -19 43 600 8 -28N03AX09 lamotrigine 2,12 3 4 4 830 3 -1N03AX11 topiramate 0,37 5 0 1 635 5 -1N03AX12 gabapentin 3,12 5 17 6 005 5 10N03AX14 levetiracetam 2,53 7 5 8 229 12 -3N03AX15 zonisamide 0,20 2 -49 920 3 -52N03AX16 pregabalin 5,19 3 -43 16 541 4 -51N03AX17 stiripentol 0,01 3 6 293 3 3N03AX18 lacosamide 0,45 8 24 4 183 23 21N03AX21 retigabine - - -100 0 - -100N03AX22 perampanel 0,06 5 -24 737 7 -27N03AX23 brivaracetam 0,03 9 131 226 29 75N04 ANTI-PARKINSON DRUGS 5,09 4 -1 18 634 4 -4N04A ANTICHOLINERGIC AGENTS 0,18 5 -7 102 5 -7N04AA Tertiary amines 0,18 5 -7 102 5 -7N04AA02 biperiden 0,18 5 -7 102 5 -7N04B DOPAMINERGIC AGENTS 4,91 4 -1 18 532 4 -4N04BA Dopa and dopa derivatives 2,27 6 -2 13 417 5 0N04BA02 levodopa and decarboxylase inhibitor 1,56 6 -3 11 295 5 1N04BA03 levodopa, decarboxylase inhibitor and COMT 0,72 6 1 2 122 6 -6

inhibitorN04BC Dopamine agonists 1,47 2 3 4 318 3 -8N04BC01 bromocriptine 0,00 19 -1 8 19 -1N04BC04 ropinirole 0,69 2 2 821 2 -18N04BC05 pramipexole 0,67 2 5 2 694 2 -6N04BC06 cabergoline 0,01 5 -3 68 5 -3N04BC07 apomorphine 0,00 2 -5 119 2 -5N04BC09 rotigotine 0,09 4 2 609 4 1N04BD Monoamine oxidase type B inhibitors 1,13 3 -5 615 4 -32N04BD01 selegiline 0,75 3 -7 356 3 -8N04BD02 rasagiline 0,38 3 0 257 5 -50N04BD03 safinamide 0,00 6 70 2 8 36N04BX Other dopamingergic agents 0,03 7 -17 182 7 -18



N04BX01 tolcapone - - -100 0 - -100N04BX02 entacapone 0,03 7 -17 182 7 -17N05 PSYCHOLEPTICS 73,18 5 0 68 905 14 -10N05A ANTIPSYCHOTICS 21,87 7 0 49 954 11 -10N05AA Phenothiazines with aliphatic side chain 0,34 7 -7 361 7 -7N05AA02 levomepromazine 0,34 7 -7 361 7 -7N05AB Phenothiazines with piperazine structure 0,45 5 -5 573 5 -4N05AB02 fluphenazine - - -100 0 - -100N05AB03 perphenazine 0,44 5 -4 550 6 -3N05AB04 prochlorperazine 0,01 2 -10 22 2 -10N05AC Phenothiazines with piperidine structure 0,01 4 -75 8 5 -72N05AC01 periciazine 0,01 4 -75 8 5 -72N05AD Butyrophenone derivatives 0,44 23 -4 523 47 -3N05AD01 haloperidol 0,42 20 -4 371 27 -3N05AD08 droperidol 0,02 96 -3 152 96 -3N05AE Indole derivatives 0,29 7 2 1 304 8 6N05AE03 sertindole 0,07 6 -8 431 6 -7N05AE04 ziprasidone 0,17 4 -8 611 5 -8N05AE05 lurasidone 0,05 18 140 262 17 146N05AF Thioxanthene derivatives 0,70 8 -7 621 12 -3N05AF01 flupentixol 0,06 4 -4 71 3 8N05AF03 chlorprothixene 0,26 3 -8 267 3 -5N05AF05 zuclopenthixol 0,38 12 -7 283 22 -3N05AH Diazepines, oxazepines, thiazepines and oxepines 13,84 7 2 20 757 12 -9N05AH01 loxapine 0,00 100 -77 5 100 -77N05AH02 clozapine 2,30 9 -1 4 953 9 -5N05AH03 olanzapine 6,22 9 5 11 605 16 1N05AH04 quetiapine 5,30 4 1 4 070 4 -32N05AH05 asenapine 0,02 13 -16 125 15 -14N05AL Benzamides 0,05 9 -6 109 9 -6N05AL01 sulpiride 0,05 9 -6 109 9 -6N05AN Lithium 0,97 6 3 607 6 3N05AN01 lithium 0,97 6 3 607 6 3N05AX Other antipsychotics 4,79 7 -6 25 094 10 -11



N05AX08 risperidone 1,91 6 2 10 159 6 -6N05AX12 aripiprazole 2,39 7 -14 6 946 13 -32N05AX13 paliperidone 0,48 13 15 7 987 12 11N05AX15 cariprazine 0,00 64 - 1 50 -N05B ANXIOLYTICS 17,44 6 -7 6 382 12 -9N05BA Benzodiazepine derivatives 15,96 6 -8 5 065 13 -11N05BA01 diazepam 4,70 9 -11 1 650 33 -22N05BA02 chlordiazepoxide 0,19 14 -65 54 13 -59N05BA04 oxazepam 4,92 4 -3 1 767 3 -2N05BA06 lorazepam 1,90 10 -2 402 8 0N05BA09 clobazam 0,36 4 6 121 4 6N05BA12 alprazolam 3,88 1 -6 1 071 1 -5N05BB Diphenylmethane derivatives 1,25 6 -5 752 5 -9N05BB01 hydroxyzine 1,25 6 -5 752 5 -9N05BE Azaspirodecanedione derivatives 0,23 9 9 565 9 10N05BE01 buspirone 0,23 9 9 565 9 10N05C HYPNOTICS AND SEDATIVES 33,86 4 3 12 570 28 -11N05CD Benzodiazepine derivatives 6,78 5 -8 3 357 13 2N05CD02 nitrazepam 0,33 3 -18 106 2 -10N05CD05 triazolam 0,03 1 -26 38 1 -26N05CD07 temazepam 6,20 4 -7 1 863 3 -2N05CD08 midazolam 0,22 44 -3 1 351 27 12N05CF Benzodiazepine related drugs 17,78 2 -7 2 668 2 -9N05CF01 zopiclone 12,97 3 -8 2 017 2 -9N05CF02 zolpidem 4,81 1 -4 652 1 -9N05CH Melatonin receptor agonists 9,08 6 53 3 413 6 6N05CH01 melatonin 9,08 6 53 3 413 6 6N05CM Other hypnotics and sedatives 0,23 6 -23 3 131 90 -35N05CM09 Valerianae radix 0,21 0 -22 309 0 -26N05CM18 dexmedetomidine 0,01 100 -36 2 822 100 -35N06 PSYCHOANALEPTICS 96,12 2 5 49 995 3 -4N06A ANTIDEPRESSANTS 74,77 2 6 31 412 2 3N06AA Non-selective monoamine reuptake inhibitors 4,35 2 2 3 309 2 5N06AA04 clomipramine 0,20 3 -1 147 3 -1



N06AA06 trimipramine 0,10 4 3 73 4 3N06AA09 amitriptyline 3,01 2 2 2 364 2 3N06AA10 nortriptyline 0,55 3 4 392 2 22N06AA12 doxepin 0,48 3 -1 332 3 2N06AB Selective serotonin reuptake inhibitors 41,20 2 3 6 635 2 -19N06AB03 fluoxetine 4,14 2 4 971 2 3N06AB04 citalopram 9,47 2 -9 1 568 2 -27N06AB05 paroxetine 2,32 1 0 716 1 -1N06AB06 sertraline 8,64 2 10 1 582 2 -36N06AB08 fluvoxamine 0,15 1 -5 83 1 -5N06AB10 escitalopram 16,47 2 8 1 714 3 -6N06AG Monoamine oxidase type A inhibitors 0,35 1 0 271 1 1N06AG02 moclobemide 0,35 1 0 271 1 1N06AX Other antidepressants 28,88 2 11 21 198 3 12N06AX03 mianserin 0,30 2 4 273 2 7N06AX05 trazodone 0,16 3 1 139 3 1N06AX11 mirtazapine 8,09 4 2 4 239 5 4N06AX12 bupropion 2,08 1 13 3 670 1 12N06AX16 venlafaxine 11,27 2 12 6 341 2 12N06AX17 milnacipran 0,05 2 -48 68 2 -47N06AX18 reboxetin 0,03 1 -1 33 1 -2N06AX21 duloxetine 3,61 2 10 1 147 3 -20N06AX22 agomelatine 0,77 3 11 1 240 3 9N06AX25 Hyperici herba - - - 0 - -100N06AX26 vortioxetine 2,53 3 50 4 049 3 49N06B PSYCHOSTIMULANTS, AGENTS USED FOR 4,60 1 5 11 432 4 0

ADHD AND NOOTROPICSN06BA Centrally acting sympathomimetics 4,55 1 6 11 106 1 1N06BA02 dexamfetamine 0,11 0 25 540 0 22N06BA04 methylphenidate 3,69 1 10 6 086 1 5N06BA07 modafinil 0,08 0 15 712 1 15N06BA09 atomoxetine 0,16 5 17 1 588 5 15N06BA12 lisdexamfetamine 0,52 1 -20 2 179 1 -20N06BC Xanthine derivatives 0,00 99 -8 275 99 -8



N06BC01 caffeine 0,00 99 -8 275 99 -8N06BX Other psychostimulants and nootropics 0,05 4 -51 52 4 -51N06BX03 piracetam 0,05 4 -51 52 4 -51N06C PSYCHOLEPTICS AND PSYCHOANALEPTICS 0,78 1 -4 468 1 -4

IN COMBINATIONN06CA Antidepressants in combination with psycholeptics 0,78 1 -4 468 1 -4N06CA01 amitriptyline and psycholeptics 0,78 1 -4 468 1 -4N06D ANTI-DEMENTIA DRUGS 15,98 5 1 6 681 6 -30N06DA Anticholinesterases 9,39 5 0 5 134 6 -35N06DA02 donepezil 6,27 4 0 411 3 -21N06DA03 rivastigmine 1,56 7 -5 3 468 7 -41N06DA04 galantamine 1,56 4 4 1 255 4 -17N06DX Other anti-dementia drugs 6,59 6 3 1 547 6 -4N06DX01 memantine 6,59 6 3 1 547 6 -4N07 OTHER NERVOUS SYSTEM DRUGS 18,06 67 -1 67 422 80 -12N07A PARASYMPATHOMIMETICS 0,25 6 5 471 44 -3N07AA Anticholinesterases 0,25 6 5 459 45 -2N07AA02 pyridostigmine 0,24 3 6 255 3 6N07AA51 neostigmine, combinations 0,01 98 -8 204 98 -10N07AX Other parasympathomimetics 0,00 4 -27 13 4 -27N07AX01 pilocarpine 0,00 4 -27 13 4 -27N07B DRUGS USED IN ADDICTIVE DISORDERS 15,04 80 -1 64 651 83 -11N07BA Drugs used in nicotine dependence 13,40 84 4 60 704 84 -8N07BA01 nicotine 12,83 88 8 57 716 88 -5N07BA03 varenicline 0,57 0 -46 2 987 0 -47N07BB Drugs used in alcohol dependence 0,66 6 -47 658 5 -40N07BB01 disulfiram 0,56 6 -51 417 6 -51N07BB04 naltrexone 0,09 5 1 150 5 0N07BB05 nalmefene 0,01 2 -10 91 3 -10N07BC Drugs used in opioid dependence 0,98 77 -10 3 289 80 -39N07BC01 buprenorphine 0,00 95 -31 17 95 -31N07BC02 methadone 0,56 86 43 1 427 91 48N07BC51 buprenorphine, combinations 0,42 67 -39 1 846 71 -59N07C ANTIVERTIGO PREPARATIONS 2,71 1 1 699 1 -7



N07CA Antivertigo preparations 2,71 1 1 699 1 -7N07CA01 betahistine 2,71 1 1 699 1 -7N07CA52 cinnarizine, combinations - - - 0 0 -64N07X OTHER NERVOUS SYSTEM DRUGS 0,05 4 -22 1 601 2 -37N07XX Other nervous system drugs 0,05 4 -22 1 601 2 -37N07XX02 riluzole 0,02 6 15 208 6 11N07XX04 sodium oxybate 0,02 1 -43 1 231 1 -43N07XX06 tetrabenazine 0,01 10 20 83 10 20N07XX07 fampridine 0,00 5 -21 79 8 -36P ANTIPARASITIC PRODUCTS, INSECTICIDES 2,35 3 2 6 224 3 -2

AND REPELLENTSP01 ANTIPROTOZOALS 2,11 3 2 3 315 4 -3P01A AGENTS AGAINST AMOEBIASIS AND OTHER 0,32 13 -5 828 9 -5

PROTOZOAL DISEASESP01AB Nitroimidazole derivatives 0,32 13 -5 828 9 -5P01AB01 metronidazole 0,32 13 -5 828 9 -5P01B ANTIMALARIALS 1,79 1 3 2 487 3 -2P01BA Aminoquinolines 1,75 1 3 1 555 1 3P01BA02 hydroxychloroquine 1,75 1 3 1 555 1 3P01BB Biguanides 0,03 6 8 798 7 -2P01BB51 proguanil, combinations 0,03 6 8 798 7 -2P01BC Quinine alkaloids 0,01 0 -38 134 0 -39P01BC02 mefloquine 0,01 0 -38 134 0 -39P02 ANTHELMINTICS 0,25 0 1 1 428 0 1P02C ANTINEMATODAL AGENTS 0,25 0 1 1 428 0 1P02CX Other antinematodals 0,25 0 1 1 428 0 1P02CX01 pyrvinium 0,25 0 1 1 428 0 1P03 ECTOPARASITICIDES, INCL. SCABICIDES, - - - 1 481 4 -1

INSECTICIDES AND REPELLENTSP03A ECTOPARASITICIDES, INCL. SCABICIDES - - - 1 481 4 -1P03AC Pyrethrines, incl. synthetic compounds - - - 1 481 4 0P03AC04 permethrin - - - 1 481 4 0P03AX Other ectoparasiticides, incl. scabicides - - - 0 - -100P03AX03 malathion - - - 0 - -100



R RESPIRATORY SYSTEM 182,12 2 -1 154 155 6 -6R01 NASAL PREPARATIONS 35,49 1 -9 24 826 1 -4R01A DECONGESTANTS AND OTHER NASAL 33,52 1 -9 19 048 1 -7

PREPARATIONS FOR TOPICAL USER01AA Sympathomimetics, plain 10,74 1 1 4 874 1 4R01AA05 oxymetazoline 0,78 0 -32 267 0 -30R01AA07 xylometazoline 9,96 1 5 4 607 1 7R01AB Sympathomimetics, combinations excl. 0,80 0 -2 540 0 0

corticosteroidsR01AB06 xylometazoline 0,80 0 -2 540 0 0R01AC Antiallergic agents, excl. corticosteroids 0,35 1 -15 314 0 -8R01AC01 cromoglicic acid 0,20 1 -34 144 1 -36R01AC02 levocabastine 0,07 0 58 104 0 58R01AC03 azelastine 0,07 0 33 67 0 37R01AD Corticosteroids 21,26 1 -12 12 888 1 -10R01AD01 beclometasone 1,13 0 1 549 0 3R01AD05 budesonide 0,52 0 -12 225 0 -20R01AD08 fluticasone 4,18 2 4 2 223 2 3R01AD09 mometasone 6,35 1 5 2 531 1 7R01AD11 triamcinolone 0,60 0 24 479 0 32R01AD12 fluticasone furoate 4,67 0 -47 2 841 0 -47R01AD58 fluticasone, combinations 3,81 1 24 4 039 1 23R01AX Other nasal preparations 0,38 4 -63 432 8 -33R01AX02 retinol - - -100 0 - -100R01AX03 ipratropium bromide 0,11 7 3 159 7 1R01AX06 mupirocin - - - 130 16 -10R01AX10 various 0,26 2 -7 143 2 -7R01B NASAL DECONGESTANTS FOR SYSTEMIC USE 1,97 2 -4 5 779 1 6R01BA Sympathomimetics 1,97 2 -4 5 779 1 6R01BA01 phenylpropanolamine 0,14 6 -2 55 6 -3R01BA52 pseudoephedrine, combinations 1,83 1 -4 5 724 1 6R02 THROAT PREPARATIONS 3,68 0 6 7 938 0 11R02A THROAT PREPARATIONS 3,68 0 6 7 938 0 11R02AA Antiseptics 1,61 0 -1 4 241 0 8



R02AA03 dichlorobenzyl alcohol 1,57 0 0 3 568 0 5R02AA05 chlorhexidine 0,03 3 -33 47 3 -32R02AA20 various - - - 626 0 44R02AB Antibiotics 1,38 1 13 2 456 1 12R02AB30 gramicidin 1,38 1 13 2 456 1 12R02AX Other throat preparations 0,70 0 12 1 242 0 18R02AX01 flurbiprofen 0,06 0 56 285 0 69R02AX03 benzydamine 0,64 0 8 956 0 8R03 DRUGS FOR OBSTRUCTIVE AIRWAY 78,12 3 -2 93 551 8 -9

DISEASESR03A ADRENERGICS, INHALANTS 43,45 3 -4 56 601 3 -13R03AC Selective beta-2-adrenoceptor agonists 14,77 3 3 8 071 2 0R03AC02 salbutamol 12,28 3 5 5 635 3 3R03AC03 terbutaline 1,20 1 3 555 1 3R03AC12 salmeterol 0,36 1 -7 520 1 -7R03AC13 formoterol 0,68 1 -6 1 001 1 -6R03AC18 indacaterol 0,17 2 -20 229 3 -19R03AC19 olodaterol 0,08 3 -19 132 3 -19R03AK Adrenergics in combination with corticosteroids or 26,71 2 -6 42 950 3 -15

other drugs, excl. anticholinergicsR03AK06 salmeterol and fluticasone 7,50 4 -5 17 977 4 -11R03AK07 formoterol and budesonide 13,53 1 2 14 932 1 -5R03AK08 formoterol and beclometasone 2,46 2 21 3 164 2 24R03AK10 vilanterol and fluticasone furoate 1,91 1 -53 4 710 1 -55R03AK11 formoterol and fluticasone 1,30 2 16 2 168 2 15R03AL Adrenergics in combination with anticholinergics 1,97 11 -18 5 579 10 -7

incl. triple combinations with corticosteroidsR03AL01 fenoterol and ipratropium bromide 0,48 7 -5 294 18 -3R03AL02 salbutamol and ipratropium bromide 0,29 50 10 627 51 -10R03AL03 vilanterol and umeclidinium bromide 0,35 3 -50 1 049 3 -50R03AL04 indacaterol and glycopyrronium bromide 0,18 3 -15 523 3 -24R03AL05 formoterol and aclidinium bromide 0,07 2 -19 205 2 -27R03AL06 olodaterol and tiotropium bromide 0,60 5 -8 1 759 5 -9R03AL08 vilanterol, umeclidinium bromide and fluticasone - - - 507 3 -

furoate



R03AL09 formoterol, glycopyrronium bromide and - - - 615 4 106 844beclometasone

R03B OTHER DRUGS FOR OBSTRUCTIVE AIRWAY 26,04 4 -2 29 659 4 -6DISEASES, INHALANTS

R03BA Glucocorticoids 19,27 2 1 18 017 3 -1R03BA01 beclometasone 2,54 2 -3 2 487 2 -4R03BA02 budesonide 4,67 3 -2 4 684 6 -3R03BA05 fluticasone 5,53 3 -1 7 447 3 -2R03BA07 mometasone 0,20 1 -7 190 1 -8R03BA08 ciclesonide 6,34 1 9 3 208 1 10R03BB Anticholinergics 6,77 8 -9 11 642 5 -13R03BB01 ipratropium bromide 0,62 48 6 277 41 6R03BB04 tiotropium bromide 5,75 4 -6 10 503 4 -9R03BB05 aclidinium bromide 0,05 2 -16 98 2 -16R03BB06 glycopyrronium bromide 0,11 2 -17 232 2 -17R03BB07 umeclidinium bromide 0,25 2 -54 532 2 -54R03BC Antiallergic agents, excl. corticosteroids - - -100 0 - -100R03BC01 cromoglicic acid - - -100 0 - -100R03BC03 nedocromil - - -100 0 - -100R03C ADRENERGICS FOR SYSTEMIC USE 0,04 3 -33 98 2 -30R03CC Selective beta-2-adrenoceptor agonists 0,04 3 -33 98 2 -30R03CC02 salbutamol 0,04 3 -33 98 2 -30R03D OTHER SYSTEMIC DRUGS FOR 8,60 2 3 7 194 68 15

OBSTRUCTIVE AIRWAY DISEASESR03DA Xanthines 0,76 3 -10 288 3 -9R03DA04 theophylline 0,74 3 -10 211 4 -11R03DA05 aminophylline 0,01 4 -20 3 4 -20R03DA54 theophylline, combinations excl. psycholeptics 0,02 1 -7 74 1 -2R03DC Leukotriene receptor antagonists 7,67 1 4 1 383 1 -15R03DC01 zafirlukast 0,02 2 -71 30 2 -71R03DC03 montelukast 7,65 1 5 1 352 1 -12R03DX Other systemic drugs for obstructive airway 0,16 41 9 5 523 88 28

diseasesR03DX05 omalizumab 0,04 85 22 2 875 85 19



R03DX07 roflumilast 0,09 6 -5 236 7 -5R03DX08 reslizumab 0,00 100 - 424 100 11R03DX09 mepolizumab 0,02 100 50 1 881 100 50R03DX10 benralizumab 0,00 100 - 106 100 -R05 COUGH AND COLD PREPARATIONS 5,38 2 -1 12 033 2 -3R05C EXPECTORANTS, EXCL. COMBINATIONS 2,79 3 -3 4 461 4 -4

WITH COUGH SUPPRESSANTSR05CA Expectorants 0,17 0 -29 248 0 -21R05CA03 guaifenesin 0,06 0 -9 81 0 -8R05CA10 combinations 0,11 0 -38 167 0 -26R05CB Mucolytics 2,62 3 -1 4 212 4 -3R05CB01 acetylcysteine 0,67 3 -2 763 4 -1R05CB02 bromhexine 1,14 0 -3 1 514 0 -3R05CB03 carbocisteine 0,06 0 -10 108 0 -9R05CB06 ambroxol 0,24 3 -3 608 3 -12R05CB13 dornase alfa (desoxyribonuclease) 0,01 7 3 305 7 0R05CB15 erdosteine 0,50 11 8 914 10 4R05D COUGH SUPPRESSANTS, EXCL. 1,15 1 -2 2 322 1 2

COMBINATIONS WITH EXPECTORANTSR05DA Opium alkaloids and derivatives 0,96 1 -3 1 742 1 1R05DA01 ethylmorphine 0,23 1 1 655 1 10R05DA09 dextromethorphan 0,73 1 -5 1 087 1 -4R05DB Other cough suppressants 0,19 0 5 580 0 5R05DB05 pentoxyverine 0,19 0 5 580 0 5R05F COUGH SUPPRESSANTS AND 1,44 1 3 4 541 1 8

EXPECTORANTS, COMBINATIONSR05FA Opium derivatives and expectorants 0,88 1 -5 2 565 1 -2R05FA02 opium derivatives and expectorants 0,88 1 -5 2 565 1 -2R05FB Other cough suppressants and expectorants 0,56 0 20 1 976 0 25R05FB02 cough suppressants and expectorants 0,56 0 20 1 976 0 25R05X OTHER COLD PREPARATIONS - - - 709 0 -44R06 ANTIHISTAMINES FOR SYSTEMIC USE 59,45 1 6 14 922 1 -3R06A ANTIHISTAMINES FOR SYSTEMIC USE 59,45 1 6 14 922 1 -3R06AA Aminoalkyl ethers 0,06 1 62 81 2 48



R06AA09 doxylamine 0,06 1 62 81 2 48R06AE Piperazine derivatives 32,45 2 4 8 032 1 -2R06AE03 cyclizine 0,05 0 -33 94 0 -33R06AE05 meclozine 0,15 0 4 349 0 4R06AE07 cetirizine 27,51 2 4 6 122 1 -1R06AE09 levocetirizine 4,74 0 4 1 468 0 -2R06AX Other antihistamines for systemic use 26,93 0 8 6 809 0 -6R06AX13 loratadine 3,26 1 5 687 1 4R06AX18 acrivastine 0,13 0 -12 157 0 -7R06AX22 ebastine 7,48 0 10 2 237 0 8R06AX26 fexofenadine 3,10 0 11 1 431 0 11R06AX27 desloratadine 12,61 0 7 2 138 1 -26R06AX28 rupatadine 0,00 0 -72 0 0 -72R06AX29 bilastine 0,35 0 5 157 0 6R07 OTHER RESPIRATORY SYSTEM PRODUCTS 0,00 100 -1 884 100 1R07A OTHER RESPIRATORY SYSTEM PRODUCTS 0,00 100 -1 884 100 1R07AA Lung surfactants 0,00 100 -1 884 100 1R07AA02 natural phopholipids 0,00 100 -1 884 100 1S SENSORY ORGANS 27,98 2 7 58 860 43 8S01 OPHTHALMOLOGICALS 27,98 2 7 56 831 45 8S01A ANTIINFECTIVES - - - 4 501 13 2S01AA Antibiotics - - - 3 815 13 5S01AA01 chloramphenicol - - - 3 223 13 5S01AA12 tobramycin - - - 9 28 -34S01AA13 fusidic acid - - - 459 5 7S01AA26 azithromycin - - - 58 0 2S01AA27 cefuroxime - - - 66 91 22S01AD Antivirals - - - 35 8 -10S01AD03 aciclovir - - - 35 8 -10S01AE Fluoroquinolones - - - 650 12 -13S01AE01 ofloxacin - - - 127 19 -47S01AE05 levofloxacin - - - 510 10 2S01AE07 moxifloxacin - - - 13 17 6S01B ANTIINFLAMMATORY AGENTS - - - 3 445 42 1



S01BA Corticosteroids, plain - - - 2 815 51 0S01BA01 dexamethasone - - - 1 434 78 1S01BA02 hydrocortisone - - - 57 0 1 748S01BA04 prednisolone - - - 814 4 -14S01BA05 triamcinolone - - - 278 100 5S01BA07 fluorometholone - - - 232 1 23S01BC Antiinflammatory agents, non-steroids - - - 630 5 5S01BC03 diclofenac - - - 91 28 14S01BC05 ketorolac - - - 6 14 -9S01BC10 nepafenac - - - 497 1 2S01BC11 bromfenac - - - 37 0 42S01C ANTIINFLAMMATORY AGENTS AND - - - 1 068 19 -20

ANTIINFECTIVES IN COMBINATIONS01CA Corticosteroids and antiinfectives in combination - - - 1 068 19 -20S01CA01 dexamethasone and antiinfectives - - - 808 23 2S01CA03 hydrocortisone and antiinfectives - - - 260 8 -51S01E ANTIGLAUCOMA PREPARATIONS AND 27,98 2 7 14 532 3 1

MIOTICSS01EA Sympathomimetics in glaucoma therapy 0,67 8 -7 449 26 -4S01EA03 apraclonidine 0,04 63 4 133 75 4S01EA05 brimonidine 0,62 5 -7 315 5 -7S01EB Parasympathomimetics 0,11 11 -7 46 54 1S01EB01 pilocarpine 0,11 11 -7 19 12 -7S01EB09 acetylcholine - - - 26 85 7S01EC Carbonic anhydrase inhibitors 2,37 3 16 1 264 3 7S01EC03 dorzolamide 0,19 5 -1 134 5 -1S01EC04 brinzolamide 1,91 3 4 681 3 4S01EC54 brinzolamide, combinations 0,27 2 - 450 2 15S01ED Beta blocking agents 13,96 2 8 7 162 2 0S01ED01 timolol 0,64 3 -4 282 3 -2S01ED02 betaxolol 0,30 3 -3 79 3 -3S01ED51 timolol, combinations 13,02 1 9 6 801 2 0S01EE Prostaglandin analogues 10,87 2 5 5 611 2 1S01EE01 latanoprost 4,83 3 3 1 805 3 -4



S01EE03 bimatoprost 3,27 1 9 992 1 8S01EE04 travoprost 0,95 3 -5 912 2 -5S01EE05 tafluprost 1,82 1 6 1 903 1 6S01F MYDRIATICS AND CYCLOPLEGICS - - - 631 64 11S01FA Anticholinergics - - - 560 63 14S01FA01 atropine - - - 25 44 15S01FA02 scopolamine - - - 59 15 8S01FA04 cyclopentolate - - - 97 58 0S01FA06 tropicamide - - - 222 56 6S01FA56 tropicamide, combinations - - - 157 97 45S01FB Sympathomimetics excl. antiglaucoma - - - 71 73 -5

preparationsS01FB01 phenylephrine - - - 71 73 -5S01G DECONGESTANTS AND ANTIALLERGICS - - - 3 733 1 19S01GA Sympathomimetics used as decongestants - - - 247 0 -4S01GA02 tetryzoline - - - 247 0 -4S01GX Other antiallergics - - - 3 486 1 21S01GX01 cromoglicic acid - - - 2 527 1 19S01GX02 levocabastine - - - 206 0 29S01GX05 lodoxamide - - - 36 0 23S01GX06 emedastine - - - 30 0 35S01GX07 azelastine - - - 24 0 235S01GX08 ketotifen - - - 611 0 21S01GX09 olopatadine - - - 52 0 10S01H LOCAL ANESTHETICS - - - 210 82 -2S01HA Local anesthetics - - - 210 82 -2S01HA02 oxybuprocaine - - - 210 82 -2S01J DIAGNOSTIC AGENTS - - - 198 60 -10S01JA Colouring agents - - - 198 60 -10S01JA01 fluorescein - - - 19 99 -62S01JA51 fluorescein, combinations - - - 179 56 6S01L OCULAR VASCULAR DISORDER AGENTS - - - 21 798 100 24S01LA Antineovascularisation agents - - - 21 798 100 24S01LA01 verteporfin - - - 203 100 -27



S01LA04 ranibizumab - - - 319 100 18S01LA05 aflibercept - - - 21 277 100 25S01X OTHER OPHTHALMOLOGICALS - - - 6 715 3 -5S01XA Other ophthalmologicals - - - 6 715 3 -5S01XA02 retinol - - - 408 3 9S01XA18 ciclosporin - - - 442 1 36S01XA20 artificial tears and other indifferent preparations - - - 5 861 3 -8S01XA22 ocriplasmin - - - 3 100 -S02 OTOLOGICALS - - - 1 776 2 7S02A ANTIINFECTIVES - - - 693 2 12S02AA Antiinfectives - - - 693 2 12S02AA03 boric acid - - - 664 2 12S02AA15 ciprofloxacin - - - 30 2 27S02C CORTICOSTEROIDS AND ANTIINFECTIVES IN - - - 861 3 8

COMBINATIONS02CA Corticosteroids and antiinfectives in combination - - - 861 3 8S02CA02 flumetasone and antiinfectives - - - 1 8 -99S02CA03 hydrocortisone and antiinfectives - - - 624 4 18S02CA05 fluocinolone acetonide and antiinfectives - - - 236 2 19S02D OTHER OTOLOGICALS - - - 222 1 -6S02DA Analgesics and anesthetics - - - 222 1 -6S02DA04 cinchocaine - - - 222 1 -6S03 OPHTHALMOLOGICAL AND OTOLOGICAL - - - 254 14 1

PREPARATIONSS03C CORTICOSTEROIDS AND ANTIINFECTIVES IN - - - 254 14 1

COMBINATIONS03CA Corticosteroids and antiinfectives in combination - - - 254 14 1S03CA04 hydrocortisone and antiinfectives - - - 254 14 1V VARIOUS 0,16 41 6 35 360 90 0V01 ALLERGENS - - - 2 369 56 11V01A ALLERGENS - - - 2 369 56 11V01AA Allergen extracts - - - 2 369 56 11V01AA02 grass pollen - - - 704 0 1V01AA03 house dust mites - - - 27 21 70



V01AA05 tree pollen - - - 1 443 79 15V01AA07 insects - - - 126 98 26V01AA11 animals - - - 69 77 8V01AA20 various - - - 1 57 18V03 ALL OTHER THERAPEUTIC PRODUCTS 0,16 41 6 8 479 78 -19V03A ALL OTHER THERAPEUTIC PRODUCTS 0,16 41 6 8 479 78 -19V03AB Antidotes - - - 4 717 97 -33V03AB14 protamine - - - 305 99 1V03AB15 naloxone - - - 85 90 -51V03AB17 methylthioninium chloride - - - 102 100 3V03AB21 potassium iodide - - - 177 45 -27V03AB25 flumazenil - - - 87 98 5V03AB33 hydroxocobalamin - - - 149 98 -24V03AB34 fomepizole - - - 122 100 -4V03AB35 sugammadex - - - 3 382 99 -39V03AB37 idarucizumab - - - 308 100 13V03AC Iron chelating agents - - - 906 4 20V03AC01 deferoxamine - - - 10 87 18V03AC02 deferiprone - - - 8 20 -41V03AC03 deferasirox - - - 888 3 21V03AE Drugs for treatment of hyperkalemia and 0,11 18 1 943 17 2

hyperphosphatemiaV03AE01 polystyrene sulphonate 0,03 25 3 119 25 3V03AE02 sevelamer 0,04 17 3 390 17 7V03AE03 lanthanum carbonate 0,04 14 -2 434 14 -2V03AE05 sucroferric oxyhydroxide 0,00 100 - 0 100 -V03AF Detoxifying agents for cytostatic treatment 0,05 95 18 1 913 95 11V03AF01 mesna - - - 487 100 24V03AF02 dexrazoxane 0,00 100 93 307 100 106V03AF03 calcium folinate 0,05 95 22 745 88 1V03AF07 rasburicase 0,00 100 -19 318 100 -13V03AF08 palifermin 0,00 100 -17 25 100 -17V03AF10 sodium levofolinate 0,00 100 -48 31 100 -48V04 DIAGNOSTIC AGENTS - - - 995 85 11



V04C OTHER DIAGNOSTIC AGENTS - - - 995 85 11V04CD Tests for pituitary function - - - 102 37 26V04CD01 metyrapone - - - 102 37 26V04CF Tuberculosis diagnostics - - - 2 70 -53V04CF01 tuberculin - - - 2 70 -53V04CL Tests for allergic diseases - - - 200 76 -11V04CX Other diagnostic agents - - - 692 95 19V06 GENERAL NUTRIENTS - - - 0 29 -90V06D OTHER NUTRIENTS - - - 0 29 -90V06DD Amino acids, incl. combinations with polypeptides - - - 0 29 -90V07 ALL OTHER NON-THERAPEUTIC PRODUCTS - - - 3 230 95 8V07A ALL OTHER NON-THERAPEUTIC PRODUCTS - - - 3 230 95 8V07AB Solvents and diluting agents, incl. irrigating - - - 3 230 95 8

solutionsV08 CONTRAST MEDIA - - - 20 149 99 7V08A X-RAY CONTRAST MEDIA, IODINATED - - - 15 102 100 7V08AA Watersoluble, nephrotropic, high osmolar X-ray - - - 96 99 -22

contrast mediaV08AA01 diatrizoic acid - - - 96 99 -22V08AB Watersoluble, nephrotropic, low osmolar X-ray - - - 15 006 100 7

contrast mediaV08AB02 iohexol - - - 12 104 100 12V08AB03 ioxaglic acid - - - 94 100 -77V08AB07 ioversol - - - 103 100 -74V08AB09 iodixanol - - - 1 190 98 11V08AB10 iomeprol - - - 1 515 99 10V08B X-RAY CONTRAST MEDIA, NON-IODINATED - - - 26 100 -32V08BA Barium sulphate containing X-ray contrast media - - - 26 100 -32V08BA01 barium sulphate with suspending agents - - - 26 100 -32V08C MAGNETIC RESONANCE IMAGING CONTRAST - - - 4 923 97 8

MEDIAV08CA Paramagnetic contrast media - - - 4 923 97 8V08CA01 gadopentetic acid - - - 0 - -100V08CA02 gadoteric acid - - - 4 599 97 9



V08CA04 gadoteridol - - - 128 99 36V08CA08 gadobenic acid - - - 3 100 -93V08CA09 gadobutrol - - - 26 100 -32V08CA10 gadoxetic acid - - - 167 99 15V08D ULTRASOUND CONTRAST MEDIA - - - 98 100 -13V08DA Ultrasound contrast media - - - 98 100 -13V08DA01 microspheres of human albumin - - - 2 100 100V08DA05 sulphur hexafluoride - - - 96 100 -14V09 DIAGNOSTIC RADIOPHARMACEUTICALS - - - 137 100 -40V09C RENAL SYSTEM - - - 44 100 30V09CA Technetium (99mTc) compounds - - - 44 100 30V09CA03 technetium (99mTc) mertiatide - - - 44 100 30V09D HEPATIC AND RETICULO ENDOTHELIAL - - - 93 100 -12

SYSTEMV09DB Technetium (99mTc), particles and colloids - - - 93 100 -12V09DB01 technetium (99mTc) nanocolloid - - - 93 100 -12V09E RESPIRATORY SYSTEM - - - 0 - -100V09EA Technetium (99mTc), inhalants - - - 0 - -100V09EA02 technetium (99mTc) technegas - - - 0 - -100V09G CARDIOVASCULAR SYSTEM - - - 0 - -100V09GA Technetium (99mTc) compounds - - - 0 - -100V09GA01 technetium (99mTc) sestamibi - - - 0 - -100V09GA04 technetium (99mTc) human albumin - - - 0 - -100V09GA06 technetium (99mTc) stannous agent labelled cells - - - 0 - -100

Hospital % Sales to hospitals and other health care units as a proportion (%) of the wholesale valueChange % is compared with equal period in previous year

page 1 drug consumption in current year (period 201801...

Documents